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Background: Until recently, evidence that protection from the bacillus Calmette–Guérin (BCG) vaccination
lasted beyond 10 years was limited. In the past few years, studies in Brazil and the USA (in Native Americans)
have suggested that protection from BCG vaccination against tuberculosis (TB) in childhood can last for
several decades. The UK’s universal school-age BCG vaccination programme was stopped in 2005 and the
programme of selective vaccination of high-risk (usually ethnic minority) infants was enhanced.
Objectives: To assess the duration of protection of infant and school-age BCG vaccination against TB in
the UK.
Methods: Two case–control studies of the duration of protection of BCG vaccination were conducted,
the first on minority ethnic groups who were eligible for infant BCG vaccination 0–19 years earlier and
the second on white subjects eligible for school-age BCG vaccination 10–29 years earlier. TB cases were
selected from notifications to the UK national Enhanced Tuberculosis Surveillance system from 2003 to
2012. Population-based control subjects, frequency matched for age, were recruited. BCG vaccination
status was established from BCG records, scar reading and BCG history. Information on potential
confounders was collected using computer-assisted interviews. Vaccine effectiveness was estimated as a
function of time since vaccination, using a case–cohort analysis based on Cox regression.
Results: In the infant BCG study, vaccination status was determined using vaccination records as recall was
poor and concordance between records and scar reading was limited. A protective effect was seen up to
10 years following infant vaccination [< 5 years since vaccination: vaccine effectiveness (VE) 66%, 95%
confidence interval (CI) 17% to 86%; 5–10 years since vaccination: VE 75%, 95% CI 43% to 89%], but there
was weak evidence of an effect 10–15 years after vaccination (VE 36%, 95% CI negative to 77%; p = 0.396).
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The analyses of the protective effect of infant BCG vaccination were adjusted for confounders, including birth
cohort and ethnicity. For school-aged BCG vaccination, VE was 51% (95% CI 21% to 69%) 10–15 years after
vaccination and 57% (95% CI 33% to 72%) 15–20 years after vaccination, beyond which time protection
appeared to wane. Ascertainment of vaccination status was based on self-reported history and scar reading.
Limitations: The difficulty in examining vaccination sites in older women in the high-risk minority ethnic
study population and the sparsity of vaccine record data in the later time periods precluded robust
assessment of protection from infant BCG vaccination > 10 years after vaccination.
Conclusions: Infant BCG vaccination in a population at high risk for TB was shown to provide protection
for at least 10 years, whereas in the white population school-age vaccination was shown to provide
protection for at least 20 years. This evidence may inform TB vaccination programmes (e.g. the timing of
administration of improved TB vaccines, if they become available) and cost-effectiveness studies. Methods
to deal with missing record data in the infant study could be explored, including the use of scar reading.
Funding: The National Institute for Health Research Health Technology Assessment programme. During
the conduct of the study, Jonathan Sterne, Ibrahim Abubakar and Laura C Rodrigues received other
funding from NIHR; Ibrahim Abubakar and Laura C Rodrigues have also received funding from the Medical
Research Council. Punam Mangtani received funding from the Biotechnology and Biological Sciences
Research Council.
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Plain English summary
I t was believed that the protection given by the bacillus Calmette–Guérin (BCG) vaccination againsttuberculosis lasted for only 10 years. This was used to define policy in the UK. Recently, some studies
have suggested that this protection could last longer. We studied how the protection changes with
time since vaccination in two situations: when BCG vaccination was given to infants at higher risk of
tuberculosis (the current policy) and when it was given at school age (UK policy until 2005). We found that
protection from infant BCG vaccination lasted for 10 years, but robust data could not be obtained to
establish vaccination status in some subjects. For vaccine given at school age, we found that protection
was substantial for at least 20 years after vaccination (vaccine effectiveness 51% from 10 to 15 years after
vaccination and 57% from 15 to 20 years after vaccination).
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Scientific summary
Background
Until recently, there was no evidence that protection against tuberculosis (TB) by bacillus Calmette–Guérin
(BCG) vaccination lasted for > 10 years. In the past few years, studies in Brazil and the USA (in Native
Americans) have suggested that protection from BCG vaccination against TB can last for several decades in
some populations. These findings were interesting and we conducted this research to add to this body of
evidence and to determine its relevance to the UK.
Establishing the duration of protection from BCG vaccination against TB is of relevance given the higher
disease risks in young adults and the increase with age in the proportion of TB cases that are pulmonary,
the main source of onward transmission. We carried out two case–control studies of the duration of
protection of BCG vaccination: one of infant BCG vaccination and one of school-aged BCG vaccination.
The studies took advantage of the UK’s long-standing universal school-aged BCG vaccination programme
and the changes introduced in 2005, when school-aged vaccination was discontinued and the programme
of selective vaccination of high-risk (usually ethnic minority) infants was enhanced.
Methods
We carried out two case–control studies in England of cases of TB and population-based control subjects
(controls), frequency matched for age. One study involved those in minority ethnic groups who were
eligible for infant BCG vaccination 1–19 years earlier. The other involved those who were UK born and
white, and who were eligible for school-aged BCG vaccination 10–29 years earlier. TB cases included in
both studies were drawn from among those notified in the years 2003–12 to the UK national Enhanced
Tuberculosis Surveillance system. Controls were recruited from the community in the areas where sampled
cases had arisen. BCG vaccination status was established based on BCG records when available, scar
reading (inspection of both arms) and BCG history (recall of vaccination). Information on potential
confounders (including demographic and social variables) was collected from cases and controls using
face-to-face computer-assisted interviews. We studied vaccine effectiveness as a function of time since
vaccination, using a case–cohort analysis based on Cox regression.
Results
In the study of infant BCG vaccination, vaccination status was based on available vaccination records as
there was poor concordance between vaccination records and either a history of BCG vaccination or scar
reading. For infant vaccination, in the subset with vaccine records, a protective effect was seen for up to
10 years following vaccination [< 5 years since vaccination: vaccine effectiveness (VE) 66%, 95%
confidence interval (CI) 12% to 85%; 5–10 years since vaccination: VE 76%, 95% CI 44% to 89%], but
there was weak evidence of an effect 10–15 years after vaccination (VE 36%, 95% CI negative to 76%;
p = 0.361). The analyses of the protective effect of infant BCG vaccination were adjusted for several
confounding variables, including birth cohort and ethnicity. Adjusting only for ethnicity, sex and birth
cohort, for which there were fewer missing data (on covariates), gave weak evidence of effectiveness
(VE 50%, 95% CI negative to 78%; p = 0.096) 10–15 years after vaccination. The high infant BCG vaccine
uptake in this high-risk ethnic minority study population and the sparsity of vaccine record data in the later
periods precluded further assessment. These results may be modified when methods to deal with missing
data are further explored.
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After school-aged BCG vaccination, a protective effect of 51% (95% CI 21% to 69%) was found 10–15
years after vaccination and a protective effect of 57% (95% CI 33% to 72%) was found 15–20 years after
vaccination, beyond which time protection appeared to wane. Ascertainment of vaccination status was
based on self-reported history and scar reading.
Conclusions
Although the findings for infant BCG vaccination in a population at high risk for TB are insufficient to
conclude that the protection extends beyond 10 years, the evidence is stronger for a moderate protective
effect for up to 20 years after school-aged BCG vaccination in the native white population. The findings
are consistent with the limited literature available.
This new evidence may be useful when making decisions on TB vaccine programmes (e.g. the timing of
the administration of improved TB vaccines, if they become available) and for cost-effectiveness studies.
Methods to deal with missing record data in the infant study could be explored, including the use of
scar reading.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research. During the conduct of the study, Jonathan Sterne, Ibrahim Abubakar and
Laura C Rodrigues received other funding from NIHR; Ibrahim Abubakar and Laura C Rodrigues have also
received funding from the Medical Research Council. Punam Mangtani received funding from the
Biotechnology and Biological Sciences Research Council.
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Chapter 1 Background
Tuberculosis epidemiology
Tuberculosis (TB) remains a significant and preventable cause of morbidity and mortality globally.
Approximately 10% of infections withMycobacterium tuberculosis progress to clinical disease.1 The World
Health Organization2 estimates that > 2 billion of the world’s population is infected. In 2014, 9.6 million
people developed symptoms of TB disease and 1.5 million died from TB.2 In the UK, after many decades
during which both the risk of infection withM. tuberculosis and the incidence of TB decreased, the last
decade of the 20th century and the first decade of the 21st century saw a steady rise in TB cases.3 From 2005
to 2011, there were around 8000 cases of TB per year in England. This declined to 6520 cases in 2014, but
England still has the highest rate of TB in Western Europe.4 There has been no decline in TB rates among the
UK-born population overall; however, the incidence of childhood TB in UK-born children, including miliary
disease and meningitis, has started to fall. TB continues to be concentrated in urban areas, with much higher
rates in the most deprived areas and in non-UK-born populations.5 Drug-resistant TB has increased among
culture-confirmed cases in the UK (the percentage resistant to any first-line drug increased from 5.6% in
1998 to 7.5% in 2005), mainly because of a rise in isoniazid resistance,6 and has remained stable.5 However,
the percentage of patients with multidrug resistance has started to fall and is < 1.4%, although complex
long-term treatment requirements and poor completion rates make such an outcome an ongoing concern.
Bacillus Calmette–Guérin vaccine effectiveness and UK policies on
bacillus Calmette–Guérin vaccination in relation to the changing
epidemiology in the UK
Bacillus Calmette–Guérin (BCG) vaccination is widely used globally. In the UK, the vaccine has mainly been
given either to infants or to adolescents at school. The protection against pulmonary TB in the UK is high when
BCG is given to tuberculin-negative schoolchildren at around age 13 years. This was shown by a trial initiated
by the Medical Research Council (MRC) in 19517 and in subsequent analyses of the effectiveness of the vaccine
given in the routine school immunisation programme.8 However, there have been variable findings with respect
to the effectiveness of the vaccine against pulmonary disease in different countries or between different studies
in the same country.7,9,10 The effectiveness of the BCG vaccine given in infancy (to prevent pulmonary TB, miliary
TB and tuberculous meningitis) has been found to be consistently high in all countries where it has been
measured.11,12 Although the World Health Organization13 recommends not to re-vaccinate, mostly because
of lack of evidence of the efficacy of revaccination, many countries implement re-vaccination programmes.
Trials in Malawi14 and more recently in Brazil15 found no increase in effectiveness or a modest increase in
effectiveness associated with repeat BCG vaccination.
Although the MRC trial of adolescent vaccination with BCG demonstrated high levels of protection in the
UK,7 there have been several subsequent policy changes in the UK with respect to BCG vaccination, prompted
by changes in the epidemiology of TB. In brief, from 1953, BCG vaccine was given to tuberculin-negative
[‘purified protein derivative (PPD)-negative’] schoolchildren at age 10–13 years, as part of the national
vaccination programme. In 1972, as the proportion of cases of TB in ethnic minority groups increased, BCG
vaccination in infancy was recommended for newborns of recent immigrants from countries with a high
incidence of TB (e.g. Indian subcontinent and Africa) as well as all refugees and asylum seekers. It was also
given to all newborns in some areas [health districts/primary care trusts (PCTs)] with a high TB incidence.
In 1991, a survey was conducted in the UK of how well the policies for BCG vaccination in the first year
of life were implemented.16 At that time, five districts offered the BCG vaccine to all newborn children,
31 districts offered it to none and 148 districts offered it to infants born to those in ethnic groups from the
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Indian subcontinent, Africa, the West Indies, China, the Middle East and South-East Asia. Of the 184
districts, 120 reported that they offered the vaccine to the newborn children of recent migrants from other
countries with a high incidence of TB.
There was discussion over whether or not BCG vaccination of the general population should be discontinued
when the risk of TB decreased, based primarily on the high number of vaccinations needed to prevent one
case of TB in the UK and worldwide.17 The International Union Against Tuberculosis and Lung Disease
(IUATLD) developed a set of criteria for the discontinuation of mass BCG programmes in low-prevalence
populations.18 IUATLD recommends that BCG vaccination be discontinued if an efficient TB notification system
is in place and:
l the average annual notification rate of smear-positive pulmonary TB is < 5 per 100,000 or
l the average annual notification rate of TB meningitis in children aged < 5 years has been
< 1 per 10 million population over the previous 5 years or
l the average annual risk of infection is < 0.1%.
The UK met all of these criteria and the BCG vaccination policy for the UK was changed by the Department of
Health in 2005 to the current policy.19 The school vaccination programme was stopped and BCG vaccination
was recommended for infants using a risk-based approach, in line with the IUATLD guidelines. In the UK,
infants are eligible for vaccination if they have a parent/grandparents originating from a high TB incidence
country or if they are born in a part of the UK with a high incidence of TB (> 40 per 100,000). It is also
recommended that some occupational groups, and uninfected contacts of TB cases, receive BCG vaccination.20
Evidence for the duration of bacillus Calmette–Guérin protection
In the UK MRC trial,7 the efficacy of the BCG vaccine by time since vaccination of adolescents at school
was estimated as 84% during the first 5 years after vaccination, 68% at between 5 and 10 years since
vaccination and 63% at between 10 and 15 years since vaccination. Although all of these estimates were
statistically significantly different from zero, the number of cases at 10–15 years post vaccination was small
and the efficacy estimate had a wide 95% confidence interval (CI) (17% to 84%). There were too few
cases between 15 and 20 years after vaccination to assess efficacy. A summary of protection by time since
vaccination, with 95% CIs (calculated by us based on the trial data presented in the paper), is provided in
Table 1. The level of protective effect in the first 10 years after vaccination was confirmed in a subsequent
cohort analysis of data from the school-aged BCG vaccination programme in England.8 There are no data
on long-term protection post-infant BCG vaccination in high-risk groups.
TABLE 1 Numbers of cases of TB in BCG vaccinated and unvaccinated groups in the MRC trial7 at different intervals
since vaccination (at age 14–15 years)
Trial group
Number of
participants
Time since vaccination (years)
0–5 5–10 10–15 15–20
Negative reaction to tuberculin,
unvaccinated
12,867 160 67 16 5
Negative reaction to tuberculin,
BCG vaccinated
13,598 27 22 7 6
Negative reaction to tuberculin,
vole bacillus vaccinated
5817 12 11 2 1
Total negative reaction,
vaccinated with either vaccine
19,415 39 33 9 7
BCG vaccine effectiveness (95% CI) (%) 84 (77 to 89) 68 (51 to 79) 63 (17 to 84) 9 (–187 to 71)
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The National Institute for Health Research stated, and we agree, that it is not known how long protection
from the BCG vaccine lasts, particularly in different age and population groups, and this hinders the
development of evidence-based policies. Until recently there was little evidence of protection lasting
beyond 10 years after vaccination at any age. In a review of published studies conducted by two of the
current authors, the pooled estimate of protection after 10 years was 14% (95% CI –9% to 32%).21
Considerable heterogeneity was observed between studies in the annual change in BCG vaccine efficacy
(VE) with time since vaccination. There was no relation between average annual change in efficacy and
overall efficacy. As with most vaccines, immunological memory may wane with time, leading to a lower
level of protection. Other explanations proposed include decreasing susceptibility among the unvaccinated
because of continued exposure to environmental mycobacteria and an increase in the proportion of
disease caused by reactivation or reinfection, against which BCG may not protect.22
An update of this systematic review of the duration of protection conferred by the BCG vaccine against TB
was conducted by our group.23 The review included the recent additional follow-up of a BCG vaccine trial
in Native Americans (who were, on average, aged 7 years when vaccinated in the 1930s), which has
reported protection lasting for several decades,24 and a cohort study in the control arm of the Brazilian
BCG re-vaccination trial, suggesting that protection lasted for 15–20 years.25
However, there is evidence from some countries of poor protection of the BCG vaccine in adult life and
much of the existing research is of uncertain relevance to the UK. The aims of this research project were
to estimate the duration of protection of the BCG vaccine given to high-risk infants in the UK and to
school-aged children in the general population. If the study provided evidence of a long duration of
protection, beyond 10 years, this would have several implications, including changing the estimates of the
cost-effectiveness of the BCG vaccine, the number of vaccinations needed to prevent a case, the possible
characteristics of new BCG-like vaccines and the timing of vaccination for any new TB vaccine developed,
that is, it would provide evidence for vaccination policies as well as inform the research and development
of new TB vaccines.
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Chapter 2 Research objectives
The aim of this study was to estimate the change in the effectiveness of the BCG vaccine in preventingTB with time since vaccination in the current UK population.
Primary objectives
l To estimate the effectiveness of BCG vaccination in preventing TB when given in the first year of life to
high-risk groups, at 5-year intervals since vaccination.
l To estimate the effectiveness of BCG vaccination in preventing TB when given in adolescence to the
general population, at 5-year intervals since vaccination, starting at 10 years since vaccination.
l To explore whether or not protection wanes with time since vaccination in high-risk groups and in the
general population.
Health technology assessed
The health technology assessed was BCG vaccination in the UK given to:
l infants at higher risk of TB (referred to throughout as ‘infant BCG’)
l schoolchildren in the general population (referred to throughout as ‘school-aged BCG’).
DOI: 10.3310/hta21390 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 39
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Mangtani et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
5

Chapter 3 Methods
Overview
Two main observational analytical studies aiming to estimate the effectiveness of the BCG vaccine against
TB by time since vaccination were conducted, as well as three supporting studies. The two main studies
were case–control studies aimed at estimating the effectiveness of (1) the BCG vaccine given to infants in
high-risk groups (results generalisable to high-risk groups in the UK) and (2) the BCG vaccine given at
school age to the general population (results generalisable to the UK population). The three supporting
studies were (1) a survey of BCG vaccination policy in England, (2) a pilot study for the main observational
studies and (3) a validation study of BCG scar reading.
In the two case–control studies, TB cases included in the study were sampled among those notified in the
years 2003–12 to the UK national Enhanced Tuberculosis Surveillance (ETS) system. Control subjects (controls)
were recruited from the community in the areas where sampled cases had arisen. BCG vaccination status was
established based on BCG records when available, scar reading (inspection of both arms) and BCG history
(recall of vaccination). Information on potential confounding variables (including demographic and social
variables) was collected from cases and controls in a face-to-face computer-assisted interview conducted by
trained staff from the National Centre for Social Research (NatCen), a leading centre for independent social
research with > 40 years’ experience in nationwide surveys. Clinical and microbiological information,
including type of disease for cases, was retrieved from the ETS system.
Ethics
The protocol for all studies, information leaflets and data collection tools were reviewed and approved by the
NHS National Research Ethics Service Committee – London and South East (reference number 11/H1102/11)
and the London School of Hygiene & Tropical Medicine Observational/Interventional Research Ethics
Committee (reference number 5996). NHS research and development permission was obtained with Public
Health England (formerly the Health Protection Agency) as the ‘NHS participating organisation’.
We report first on the policy survey (one of the supporting studies) and then on the two main
observational studies.
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Chapter 4 Survey of infant bacillus
Calmette–Guérin vaccination policies in England
Background
There appeared to be widespread variation at the local level in the implementation of the
recommendations for infant BCG vaccinations as well as in vaccine delivery pathways.
A survey of both past and current vaccination policies was conducted to support the main studies by
assessing what infant BCG vaccination provision was in place prior to 2005 in local areas and to identify
and engage with services or individuals on the delivery pathway who managed or had access to
vaccination records.
Methods
We designed a standardised, mostly close-ended structured questionnaire covering both the historical and
the current BCG vaccination policy in and outside infancy, eligibility criteria and their documentation,
delivery pathways and constraints to service delivery. The questionnaire was tested by asking immunisation
co-ordinators from four London PCTs to complete it and questions were then adjusted accordingly.
We surveyed all 152 PCTs, the local administrative areas for health-care services in England between
November 2010 and March 2011. We also checked PCT websites and related NHS sources for publicly
available documents to assess agreement with the questionnaire data received. Details of the survey are
published as a peer-reviewed paper.26
We also obtained the source data (original questionnaires/tables) from previous BCG policy surveys16,27
from the investigators to complement information on historical infant vaccination policies.
Results
Questionnaires were returned from 85% (129/152) of the PCTs in England. There were no differences in TB
notification rates between responding and non-responding PCTs. We found publicly available current BCG
policy documents for 114 of the 129 (88%) PCTs that responded. Two (2%) PCTs were excluded from the
subsequent analysis because their BCG policies could not be determined clearly from their responses.
Current bacillus Calmette–Guérin vaccination policy
The agreement with publicly available BCG vaccination policy documents was high, with only three (2%)
PCTs reporting policies that were different from the information in these documents. Details of the
findings are provided elsewhere.26 In summary, the new policy for the delivery of infant BCG in high-risk
groups had been implemented in all PCTs, but with considerable heterogeneity with regard to the
organisation of the delivery of the vaccine and some difficulties experienced in the identification of eligible
children. Sixteen of the 127 (13%) PCTs reported universal infant vaccination and 111 (87%) reported
selective infant vaccination. PCTs with a selective infant vaccination policy most frequently vaccinated on
postnatal wards (51/102, 50%), whereas PCTs with a universal infant vaccination policy most frequently
vaccinated in community clinics (9/13, 69%; p = 0.011). All (100%) PCTs that vaccinated primarily on
postnatal wards did so during the infants’ first month of life, whereas only 13 out of 37 (35%) PCTs that
mainly vaccinated in community clinics did so in the infants’ first month of life (p < 0.001).
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Past (pre 2005) bacillus Calmette–Guérin vaccination policy
Before 2005, the national policy was to vaccinate all tuberculin skin test (TST)-negative schoolchildren
aged 11–14 years. The TST was performed by school nurses, who also administered the vaccine in eligible
children. However, the 1983 survey of BCG vaccination policies reported that five health authorities had
stopped their routine BCG vaccination programme for schoolchildren (two in 1974 and one each in 1977,
1980 and 1983) and replaced it with selective infant BCG vaccination targeting immigrants.27 By 1992, at
least 15 health authorities in England and Wales had stopped their routine BCG vaccination programme
for schoolchildren, mostly in areas with very low TB notification rates.16 This later survey also found that
18 health authorities offered BCG vaccination to selected groups at school entry, mostly recent immigrants,
although this was offered in only two of the 15 districts that had discontinued BCG vaccination for
schoolchildren.16
Infant bacillus Calmette–Guérin vaccination pre 2005
The 1983 survey of BCG vaccination policies found that six of the 201 health districts in England and
Wales had universal infant BCG programmes, with a further 98 health districts already having some
form of selective infant BCG programme, mostly targeting newborns of immigrants and/or neonatal TB
contacts.27 The 1992 survey reported that, of the 184 health districts surveyed, five had a universal infant
BCG programme and 148 had a selective infant BCG programme (including 14 of the 15 districts where
vaccination of schoolchildren had been discontinued).16 The main groups targeted in areas with selective
policies were infants from ethnic minority groups (all 148 districts) and recent immigrants from high TB
burden countries (120 districts), as well as infants from families with a history of TB (40 districts). This
survey also found that only one of the 31 health districts with no infant BCG vaccination programme had
an estimated population of Indian subcontinent origin of > 10%.
Overall, therefore, these previous surveys suggested that about half of the health districts in England and
Wales already offered the BCG vaccine to ethnic minority infants by 1983, with > 80% doing so by 1992,
including nearly all areas with an estimated population of Indian subcontinent origin of > 10%.
Bacillus Calmette–Guérin vaccine administration
In 1983, 152 out of 201 (76%) health districts vaccinated using a syringe and needle exclusively, 14 used
a jet injector and 25 used either of these methods at the discretion of the provider. Two districts used
the multipuncture method.27 By 1992, 163 out of 169 (96%) health districts still implemented routine
vaccination of schoolchildren using a needle and syringe, with three using the multipuncture method and
one using a jet injector. All districts offering infant BCG administered it using a syringe and needle.16
Discussion
The data for this survey were collected during and after a major reorganisation of the NHS. This
complicated access to key informants, as staff responsibilities at this time were not clear. The potential
implications of the recent NHS reorganisation for BCG vaccination policies at the local level are also not
now reflected in this report.
Implications of the findings for the main studies
One of the main features of BCG vaccination policies in England highlighted by this survey and the previous
surveys is the substantial heterogeneity in infant BCG policies between health areas, as well as the changes
over time. However, there are several consistent patterns that are relevant to the main studies:
l Up to 1992, > 90% of health districts still had a routine universal vaccination programme for
schoolchildren. Given that the birth cohorts eligible for the main study of BCG vaccination in the
general population are subjects born from 1965 to 1989, it is reasonable to assume that most of the
target population had similar opportunities for vaccination/exposure to the vaccination programme
for schoolchildren.
SURVEY OF INFANT BACILLUS CALMETTE–GUÉRIN VACCINATION POLICIES IN ENGLAND
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l From 1983, > 50% of health districts had an infant BCG programme, with ethnic minority groups
being the prime population target; this had increased to > 80% by 1992. Furthermore, all but one
district with > 10% of residents being of Indian subcontinent origin (the majority minority ethnic group
in England and Wales) had an infant BCG programme.
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Chapter 5 Observational studies of bacillus
Calmette–Guérin vaccine effectiveness with time since
vaccination in England
Objectives
The primary objectives of the observational studies were to:
l estimate the effectiveness of BCG vaccination in preventing TB when given in the first year of life
(‘infant BCG’) to high-risk groups, in 5-year intervals since vaccination
l estimate the effectiveness of BCG vaccination in preventing TB when given at school age (‘school-age
BCG’) to the general population, in 5-year intervals since vaccination, starting 10 years after vaccination.
For both exposures it was also explored whether or not protection wanes with time since vaccination.
Methods
Study design and study areas
Participants in both studies were recruited using a case–control design. For logistical efficiency, the
recruitment for the infant BCG study was restricted to areas of England with a ≥ 30% resident black and
Asian minority ethnic (BAME) population, based on the 2001 general census. These communities are
geographically clustered. The school-age BCG study was carried out across England, reflecting the much
larger geographical spread of TB cases in the target population. A pilot study to test the methods for
recruiting controls was conducted first.
Pilot study
The main objectives for the pilot study were to:
l estimate the response rate for cases to allow the sampling strategy to be refined
l assess the feasibility of the control recruitment strategy (nominated controls)
l field test the operating procedures and the questionnaire.
A total of 115 subjects with a previous TB diagnosis notified to the ETS system were selected and invited
to take part, 58 for the infant BCG study and 57 for the school-age BCG study. Those successfully
recruited were invited to nominate up to five unrelated acquaintances of a roughly similar age, sex and
broad ethnic background residing in the fieldwork area to serve as controls.
Study main exposure and primary outcome
Infant bacillus Calmette–Guérin study
l Main exposure: BCG vaccination given in infancy to subjects at higher risk of TB (study population
restricted to BAME populations as they were the main target of the vaccination programme),
as recommended by UK Department of Health guidelines.20
l Primary outcome: level and duration of BCG-derived protection against any notified TB disease up to
19 years after vaccination.
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School-age bacillus Calmette–Guérin study
l Main exposure: BCG vaccination given to TST-negative schoolchildren as part of the UK universal
school BCG vaccination programme until 2005, when it was discontinued.
l Primary outcome: level and duration of BCG-derived protection against any notified TB disease from
10 to 29 years after school-age vaccination.
Participants
Infant bacillus Calmette–Guérin study
Cases were UK-born subjects from a BAME background with a confirmed first TB episode diagnosed and
notified to the Public Health England ETS system between 2003 and 2012, aged between 1 and 19 years
at the time of diagnosis (i.e. born between 1984 and 2012) and residing in the study area at the time of
diagnosis. The BAME populations included those from high TB burden settings and were any black or
South Asian populations, including those from India, Pakistan, Bangladesh, Nepal, Bhutan, the Maldives
and Sri Lanka (including those whose families were originally from these backgrounds but who migrated
to Britain from other regions, e.g. the Caribbean or east or southern Africa).
Controls were population-based UK-born subjects from the same target BAME backgrounds, residing in the
same study area as cases, from the same birth cohorts as cases (i.e. born between 1984 and 2012) and with
no previous episode of TB. Controls were frequency matched to cases within 5-year birth cohorts.
Cases with known human immunodeficiency virus (HIV) infection were not included in the study. This
criterion was not applied to controls because the prevalence of HIV infection in the general population
from which they were sampled was small. Cases and controls from BAME backgrounds other than those
targeted (e.g. Chinese, Japanese, Korean) were not included.
School-age bacillus Calmette–Guérin study
Cases were UK-born subjects from a white ethnic background with a confirmed first TB episode diagnosed
and notified to the Public Health England ETS system, residing in England at the time of diagnosis between
2003 and 2012 and aged between 23 and 38 years at the time of diagnosis (i.e. born between 1965 and
1989). BCG vaccination was routinely offered to schoolchildren aged about 13 years (range 10–15 years)
and so the age range of cases would allow measurement of the effect of the vaccine from about 10 to
29 years after vaccination.
Controls were UK-born subjects from a white ethnic background residing in England, from the same birth
cohorts as cases (i.e. born between 1965 and 1989) and with no previous episode of TB. Controls were
frequency matched to cases within 5-year birth cohorts.
Cases with known HIV infection were not included. This criterion was not applied to controls because the
prevalence of HIV infection in the general population from which they were sampled was small.
Sample size
The sample size calculations for both studies were based on assumptions around expected BCG vaccine
uptake and minimum level of VE for successive time bands since vaccination for the different populations.
All calculations were carried out for a frequency-matched case–control study design, with 90% power and a
5% significance level. Numbers were inflated by 15% to allow for post-recruitment exclusions because of
ineligibility and loss of power after controlling for confounding variables. For the infant BCG study, at a ratio
of case to control of 1 : 1, we estimated the required sample size to be 627 cases and 627 controls. For the
school-age BCG study, the number of eligible cases available to be invited was limited and, hence, the
sample size was estimated for an average ratio of up to two controls per case, for a total of 665 cases and
1183 controls. The ratio of 2 : 1 was applied to mitigate the effect on statistical efficiency of an expected
OBSERVATIONAL STUDIES OF BACILLUS CALMETTE–GUÉRIN VACCINE EFFECTIVENESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
14
low case recruitment rate, based on the results of the pilot study; however, the intention was to recruit as
many cases as possible. The detailed sample size estimates for each study are presented in Tables 2 and 3.
Study sampling
Selection of cases
For both studies, eligible TB cases were identified from the ETS database based on the date of diagnosis
and reported date of birth, residential address at the time of diagnosis and self-reported ethnic
background. Cases with a reported previous TB episode or with a previous notification of TB in the
database were not included. For the infant BCG study, cases were included if they resided in the study
area (defined to include small areas where ≥ 30% of the population were from BAME groups). For the
school-age BCG study, the study area included all of England.
Selection of controls
The procedure for selection of controls was amended after the pilot study. We required community-based
controls who represented the population in which the cases occurred. We had two potential strategies
for this: the first, which was lower cost but high risk, was nominated controls. We piloted this strategy
to recruit individually matched controls among unrelated acquaintances nominated by cases. The pilot
study indicated that recruiting nominated controls was not feasible: people either were reluctant to
nominate friends or reported that they did not have friends of an eligible age or ethnicity. The control
recruitment strategy was thus changed to our second-choice strategy (more resource intensive but lower
risk): self-weighted multistage stratified sampling of the target populations across the area from which
cases were recruited. Multistage sampling was preferred to straightforward simple random sampling (SRS)
to ensure wider geographical coverage of the respective study areas while maintaining reasonable
clustering of field data collection for optimal logistical efficiency.
TABLE 3 Sample size estimates for the school-age BCG study
Age at TB
diagnosis
(years)
Time since
vaccination
(years)
Assumed BCG
uptake (%)
Minimum VE to
be detected (%)
Frequency-matched design with
ratio of two controls per casea
Cases, n Controls, n
23–27 10–14 80 60 116 (145) 232 (258)
28–32 15–19 80 50 208 (260) 416 (463)
33–37 20–24 80 50 208 (260) 416 (463)
Total number in school-age BCG sample 532 (665) 1064 (1184)
a It was possible that about 10% of controls and 20% of cases would not be eligible (discarded) because they were
tuberculin positive (PPD+); hence, the numbers in parentheses were the actual recruitment targets taking this into account.
TABLE 2 Sample size estimates for the infant BCG study
Age at TB
diagnosis
(years)
Time since
vaccination
(years)
Assumed BCG
uptake (%)
Minimum VE to
be detected (%)
Frequency-matched design with
ratio of one control per case
Cases, n Controls, n
0–5 0–5 90 60 252 252
6–12 6–12 80 60 158 158
13–17 13–17 60 50 217 217
Total number in infant BCG sample 627 627
DOI: 10.3310/hta21390 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 39
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Mangtani et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
15
For the infant BCG study we used a two-stage self-weighted sampling design. Based on previous work by the
Health Survey for England28,29 and the 2001 census,30 we estimated that, on average, screening 12 residential
addresses would result in one eligible (based on BAME group and birth cohort) control successfully recruited
from the community. A total of 7750 addresses were selected probability proportional to size (PPS) of the
eligible BAME population in the study area, which consisted of geographical areas with ≥ 30% BAME
residents based on the 2001 census. Intercensus estimates were not thought to be as robust and were not
available by small areas.
The first stage consisted of sampling the lower-level super output areas (LSOAs) with a ≥ 30% resident
BAME population by PPS. LSOAs are designed to have a fairly socially homogeneous population of, on
average, 1500 residents each.31 A total of 2659 out of 32,482 (8.2%) LSOAs had ≥ 30% BAME residents,
accounting for 50% (2,027,398/4,024,287) of the total BAME population in England. The study area also
included 60% of all eligible TB cases in these groups notified to the ETS system.
The second stage involved SRS of seven residential addresses within each LSOA selected in the first stage.
This was carried out using the small-user Postcode Address File. To ensure equal geographical spread of
selected addresses within the LSOA, we randomly sampled seven distinct postcode units in each LSOA and
then one address per postcode unit. Postcode units each include, on average, 15 residential addresses and
LSOAs include, on average, 30 postcode units each.
Overall, 1107 LSOAs were sampled with PPS out of 2659 LSOAs with ≥ 30% BAME residents and, in each
selected LSOA, seven residential addresses were selected using SRS.
For the school-age BCG study we used a three-stage self-weighted sampling design to reflect the much
wider study area (the whole of England). We estimated that a total of about 9500 residential addresses
would have to be screened to meet our target, based on an average of one eligible control successfully
recruited from every seven to eight addresses screened, based on the Health Survey for England28,29 and
2001 census30 data broken down by age and ethnicity.
The first stage was the selection of 449 mid-level super output areas (MSOAs) out of a total of 6781 in
England, with PPS of their 2010 mid-year estimates of the population aged 25–49 years.32 MSOAs consist
of contiguous LSOAs, constrained by the 2003 local authority boundaries; each has a minimum population
of 5000 and an average of 7200 inhabitants.31
The second stage was the random selection of three LSOAs in each MSOA, by PPS.
The third stage was the selection of seven residential addresses from each LSOA by SRS using the same
procedure as for the infant BCG study.
In total, we selected 449 out of 6781 MSOAs and a total of 1347 LSOAs across England (three per
MSOA). Seven randomly sampled addresses were selected in each LSOA. A few addresses (n = 6) no
longer existed, leaving a total of 9423 addresses screened for eligible controls.
Summaries of the sampling strategies for the infant BCG study and the school-age BCG study are provided
in Figures 1 and 2, respectively.
Data sources
Data for the studies were obtained from four main sources.
Face-to-face interviews
The core study data, including indicators of BCG status (vaccination history, inspection of both arms for
vaccination scar and personally held vaccination record or card, e.g. the ‘red book’), were collected in the
community through computer-assisted personal interviews (CAPIs) carried out by trained and experienced
field interviewers. These data are referred to as CAPI data in this report.
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England LSOAs
(n = 32,482)
Study area – LSOAs with a > 30% BAME population 
(n = 2659) (includes 50% of the overall BAME population 
in England)
LSOA sampled with PPS ethnic
minority resident populationa
(n = 1107)
Controls to recruit
(n = 627)
 (≈1 out of 12 addresses productive)
Frequency matched to cases on 
year of birth and sex
TB cases in restricted study area
7 addresses/LSOAs (total n = 7750)
sampled using SRS of postcodes
Cases in restricted area notified 
to the ETS database (> 85% reporting
completeness)
Cases to enrol
(n = 627)
FIGURE 1 Summary of the sampling strategy for the infant BCG study. a, LSOA sampled at random using
probability proportional to size of the number of residents from ethnic minority background in the LSOA.
Study area – England
6781 MSOAs = 32,482 LSOAs
7 addresses/LSOAs (total n = 9423)
sampled using SRS of postcodes
Controls to recruit
(n = 1183)
 (≈1 out of 7–8 addresses productive)
Frequency matched to cases on 
year of birth and sex
449 MSOAs sampled with PPS 
25–49 years resident population
All eligible TB cases in England
3 LSOAs/MSOA (total n = 1347)
sampled with PPS resident 
25–49 years population 
Cases notified to the ETS database
(> 85% reporting completeness)
Cases to enrol
(n > 665)
FIGURE 2 Summary of the sampling strategy for the school-age BCG study.
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Surveillance register
Clinical information on TB cases was obtained from Public Health England’s ETS system. These data are
referred to as ETS data in this report.
NHS vaccination records
Information on BCG vaccination held by the NHS was requested from, and manually searched for in,
the Child Health Information Systems (CHISs) of NHS PCTs, as well as NHS community care trusts,
in areas where participants resided at the time when eligible for vaccination. These data are referred to
as NHS records in this report.
Other
Small area-level (LSOA) Indices of Multiple Deprivation (IMD) – a proxy measure for socioeconomic status –
were obtained from the Office for National Statistics (ONS) English Indices of Deprivation 201033 by
linkage, using study participants’ residential postcode. Local annual TB rates in the areas of residence (local
authorities from 1988 to 1990 and PCTs from 2005 to 2007) when subjects were eligible for vaccination
were obtained from Public Health England historical data.
Study variables
Indicators of vaccination status
Data were collected on four indicators of BCG vaccination status: history (recall from parent or
respondent), the inspection of both arms for a BCG scar by the interviewer following a standardised
procedure, personal vaccination record (red book) or card, and NHS vaccination record. All four indicators
were incomplete and had strengths and limitations in the two different studies:
1. Vaccination history. For the infant BCG study, information was collected from parents or subjects
(if older and living away from home, although they were encouraged to check information with their
parents over the telephone). Subjects were, of course, not able to remember vaccination in the first year
of life and parents’ reports were subject to considerable recall bias because BCG vaccination was
confused with any of the several other vaccinations given in infancy. For the school-age BCG study,
BCG vaccination history was less likely to be affected by recall error as the BCG vaccine was the sole
vaccine routinely given at school in all children aged around 13 years (an age that they could recall).
2. Inspection for BCG scar. Interviewers were trained to recognise a BCG vaccination scar and inspected
both arms after consent was obtained. Higher refusal rates were noted among young/teenage female
cases with family origins in Africa and Pakistan.
3. Personal vaccination record. Study participants were encouraged to look for any vaccination record or
card ahead of the interview. The most common personally held vaccination record (commonly known as
the red book) was introduced in England in the mid-1990s; thus, these records were missing for older
participants in the infant BCG study. No participants in the school-age BCG study had hand-held records.
4. NHS vaccination record. For the infant BCG study, vaccination was checked through the CHIS in local
area health trusts. There were several practical challenges to this: the decentralisation of primary health
care in the NHS, with heterogeneity in how data are stored and procedures to request authorisations
between trusts; the major NHS reform that coincided with our study period, which meant that not
every trust could be successfully contacted to check their records; and the fact that CHIS records are
discarded or archived according to regulatory requirements when individuals reach a certain age,
varying from 21 to 25 years depending on the area. For the school-age BCG study, there was no
central database of school vaccination records and this information was inconsistently recorded in the
CHIS. NHS vaccination records were therefore not available for nearly all participants.
Tuberculosis events
Information on the date of notification of TB events, as well as the reported date when symptoms started
and the date of diagnosis for all cases, was retrieved from the ETS system. We also extracted data on the
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site of disease as well as checking that no previous TB episode had been reported. Controls were asked for
any past TB diagnosis and their details were also checked against the ETS system for any notified TB events.
Other variables/potential confounders
l Basic demographics, including date of birth, sex and ethnic background (CAPI). Ethnic background was
self-assessed, choosing from the standard ONS categories in the latest UK general population census.
l Education level (CAPI). For the infant BCG study we collected information on the education level of both
parents and for the school-age BCG study we collected information on participants’ education level.
l Small-area level deprivation index. The postcodes of cases at the time of diagnosis as well as those of
controls were used to obtain the LSOA-level IMD scores and ranks, a proxy measure of socioeconomic
status. The IMD, a composite measure of deprivation generated by the ONS, combines scores in seven
deprivation domains (income, employment, health and disability, education, skills and training, crime
and living environment).33
l Household crowding (CAPI). Information was collected on the number of residents in the household
and the total number of rooms (excluding kitchen and bathroom) and the number of bedrooms. This
was used to generate two commonly used measures of crowding, the number of persons per room
and the number of persons per bedroom.34,35
l Background risk of TB. Data were collected on the broad world region of origin of parents and
grandparents, as well as frequent travel and/or prolonged stays (≥ 3 months) to parts of the world with
a high TB burden.
l Lifestyle/behaviour risk factors (CAPI). For the school-age BCG study, participants were asked about
potential risk behaviours, including their history of tobacco smoking, alcohol abuse, drug misuse, stays
in prison and homelessness.
l Other. Information was collected on areas of residence of participants between birth and age 14 years.
Historical average TB notification rates in those areas at relevant time periods were retrieved as a proxy
measure of the local TB epidemiology.
Ethics and consent
Eligible subjects were given detailed information on the relevant study by way of an information leaflet
and a dedicated webpage; an opportunity was also provided for them to ask clarification questions. For
those willing to take part in one of the studies, we obtained up to three separate informed consents:
(1) for the face-to-face interview, (2) for the inspection of both arms for a BCG scar (as well as photographs
for about 25% of participants) and (3) for permission to contact the NHS using their personal details to check
their vaccination records for BCG vaccination. Subjects aged < 16 years provided assent, with formal consent
obtained from their parent or legal guardian.
All subjects contacted about one of the studies were given the option to opt out following the initial
invitation, in which case no further contact was attempted by the field worker. Subjects could also freely
withdraw from the study at any stage, including during the interview, or afterwards by telephone, and
their data would be deleted.
Participants in the study were given a £15 gift voucher as compensation for their time, irrespective of
whether they completed the interview or withdrew their consent at any stage.
Field procedures and data collection
The pilot study for the recruitment of cases and nominated controls was carried out in September and
October 2011.
The main change instigated after the pilot study was the approach to the recruitment of controls
(see Selection of controls). After preparations for the new approach to the recruitment of controls were
complete, data collection for the main studies was conducted from February 2012 to September 2014.
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Cases were sent an information letter inviting them to take part in the study and were offered the
opportunity to request further information or opt out either by telephone or by returning an opt-out slip.
Controls at the residential addresses selected for screening were sent a similar advance information letter,
which also included an opportunity to opt out, as for cases.
Trained interviewers attempted contact with both the invited cases and the selected control residential
addresses using a standard visit schedule, including weekdays and weekend days and morning, afternoon
and evening visits. For controls, the residents at sampled addresses were first screened for eligibility. If
required at the door, a translation screening card with 17 of the most common other languages spoken in
England was used to ask which language was their first language, together with a show card asking for
their help with the study in their first language. Eligible controls were provided with information on the
study. Informed consent was obtained from all those who were eligible and willing to participate in the
study before face-to-face interviews were conducted.
Study participants aged ≥ 16 years were interviewed directly. Parents or those with parental responsibility
were interviewed for participants aged 0–15 years. For the infant BCG study, in which some parents from
BAME groups were not fluent in English, translation (from the 17 most commonly spoken foreign
languages in England) was offered if requested.
All interviews were carried out by experienced staff from NatCen, a leading independent social research
not-for-profit organisation that routinely conducts large-scale national surveys (e.g. Health Survey for
England, National Survey of Sexual Attitudes and Lifestyles). All interviewers undertook a day’s training
specifically for this study before taking part in any fieldwork, including carrying out homework and
intensive practical training on the inspection of both arms to identify BCG vaccination scars. The training in
scar reading included the use of photos and volunteers with and without scars.
Monitoring and quality control during field data collection included formal supervisory field visits to
individual interviewers and blind telephone recall of at least a 10% random sample of study participants,
checking for quality of the face-to-face interviews and compliance with protocols and procedures for
interviewing, as well as other specific instructions.
The CAPI included a standardised pretested questionnaire with only close-ended questions and a preset
standard script that interviewers had to read. Part of the questionnaire for the school BCG study collected
sensitive data on tobacco, alcohol and controlled substance use, and previous stays in prison via a
computer-assisted self-interview during which the interviewees entered the data themselves and then
locked the data to be inaccessible to the interviewer before returning the laptop to him or her.
Information on a range of other potential confounding variables was collected during the interviews,
including indicators of socioeconomic status, education level, household crowding and lifestyle behaviours.
Analysis
Data cleaning and descriptive analysis
For both studies, data from the different data sources were merged, cleaned and checked using
consistency and range checks. The distribution of quantitative variables was examined and they were
transformed into categorical variables as required (IMD scores, birth year). The distribution of covariates
and any missing data on them were summarised by case/control status.
Definition of vaccination status
Infant bacillus Calmette–Guérin study
After exploration of completeness, agreements between the different indicators of vaccination status were
assessed. Based on the assessment we judged that BCG vaccination status was best defined using
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combinations of observed vaccination records, as described in Table 4. Briefly, the recording of BCG
vaccination in either the red book or NHS records was used as evidence of previous BCG vaccination.
Subjects were classified as unvaccinated only if both records were available and BCG vaccination was not
recorded in both records. The date of BCG vaccination was taken as that reported in the vaccination records.
School-age bacillus Calmette–Guérin study
After checking for completeness, BCG vaccination status was based on the two indicators available, that is,
self-reported history and scar inspection. Self-reported history was based on recall of the TST prior to
vaccination and subsequent BCG vaccination; participants’ self-reported BCG vaccination history was,
therefore, classified into three categories:
1. convincing history of BCG vaccination – subjects who recalled the TST and subsequent BCG vaccination
48–72 hours later or post-vaccination soreness, pustule and/or scar
2. probably BCG vaccinated – those who reported receiving the BCG vaccination at school but who did
not recall the TST and/or post-vaccination soreness, pustule or scar
3. not vaccinated – subjects who reported never receiving the BCG vaccination.
Self-reported history was combined with the result of inspection of the arms for a scar to define BCG
vaccination status, as detailed in Table 5. Briefly, subjects with a convincing self-reported history of BCG
vaccination, or a probable history of BCG vaccination or a scar were classified as vaccinated. Those with no
history of BCG vaccination and no scar at inspection, or either, were classified as not vaccinated.
Those with a history of vaccination reported the age when they were vaccinated, but the exact date of
vaccination was not available and so a date of vaccination was assigned randomly by sampling dates
within the year corresponding to the age at vaccination (excluding the school holiday months of July
and August), using a uniform distribution. For those for whom the age of vaccination was not available
(e.g. ‘possibly vaccinated’ based on scar), the age at vaccination was assigned to be age 12 years, which
was the median age at vaccination among those for whom age at vaccination was available.
Association between time since bacillus Calmette–Guérin vaccination and risk
of tuberculosis
We investigated the association between time since vaccination and risk of TB in two steps.
1. First, we estimated the association for successive time since vaccination intervals of approximately
5 years: 1–5, 5–10, 10–15 and 15–19 years after vaccination for the infant BCG study and 10–15,
15–20, 20–25 and 25–29 years after vaccination for the school-age BCG study.
2. Second, we modelled VE smoothly as a function of time since BCG vaccination.
TABLE 4 Definition of BCG vaccination status for the infant BCG study using both vaccination records
Red book NHS records BCG vaccination status (definition 1)
BCG vaccination recorded BCG vaccination recorded Vaccinated
BCG vaccination recorded BCG vaccination not recorded
BCG vaccination not recorded BCG vaccination recorded
BCG vaccination not recorded BCG vaccination not recorded Not vaccinated
BCG vaccination not recorded Missing Treated as missing
Missing BCG vaccination not recorded
Missing Missing Missing
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Statistical methods
The data were analysed using the case–cohort approach,36,37 with controls forming the ‘subcohort’, that is,
the set of potential controls for each case. This provided an efficient analytical approach to the data, which
made best use of data for controls throughout the time that they were at risk and allowed flexible modelling
of VE by time since vaccination.38 This approach was appropriate because our controls were sampled at
random from the underlying population within which cases arose (with frequency matching on year of birth)
and because the outcome (TB) is rare in the underlying population (with annual TB notification rates in our
study populations in the tens per 100,000); the controls can therefore be considered approximately as
random samples from the underlying population within each of the frequency-matching strata.
Under our selected approach, each case was compared at its event time with all controls in the subcohort
who were still at risk at that time and who were in the same stratum as the case. The statistical analyses
assumed an underlying Cox proportional hazards model, the parameters for which were estimated using a
pseudopartial likelihood analysis with robust standard errors; the latter is necessary in case–cohort analyses
to account for the ‘shared’ control groups between cases.
Follow-up started for all participants from their date of birth (i.e. analyses were done on the age time
scale). Time at risk was accrued from the age at which participants would have been eligible for BCG
vaccination, corresponding to the first birthday for participants to the infant BCG study (when most would
have had an opportunity to receive infant BCG vaccination). In both studies, the basic model for VE was
stratified by year of birth and adjusted for sex. Allowing separate baseline hazards within each year of birth
was used to account for frequency matching of controls on year of birth. For the infant BCG study, given
that not only the risk of TB in each ethnic group is different but also the age distribution of cases, the
baseline hazard was also allowed to vary by ethnic group. Other covariates were then added in turn in the
basic model to assess the potential confounding effect by examining changes in the point estimates and
the standard errors, and a final multivariable model was then built.
We present the results as hazard ratios (HRs) and corresponding 95% CIs. VE estimates can be computed
as VE = 1 – HR).
TABLE 5 Definition of BCG vaccination status for the school-age BCG study
Self-reported historya Scar inspection BCG vaccination status
Convincing BCG vaccination history Scar present Vaccinated
Convincing BCG vaccination history No scar
Convincing BCG vaccination history Not inspected
Probable BCG vaccination history Scar present
Probable BCG vaccination history No scar
Probable BCG vaccination history Not inspected
No BCG vaccination history Scar present
Unsure Scar present
No BCG vaccination history No scar Not vaccinated
No BCG vaccination history Not inspected
Unsure No scar
Unsure Not inspected Missing
a If there was recall of being given BCG at school and either a clear recall of a prior tuberculin skin test or a pustule or
scarring post vaccination, this was categorised as a convincing history; if only recall of BCG at school, it was categorised
as probable.
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We modelled VE smoothly as a function of time since vaccination using two methods. First, we used a
restricted cubic spline with three knots, with the knots reflecting the time intervals of each study. Second,
we fitted a simpler model in which the log HR associated with BCG vaccination was assumed to change
linearly with time. The results were displayed graphically as smooth curves, including 95% confidence
limits. The results from the linear model were also tabulated.
Handling of missing data
The results presented in this report are based on ‘complete-case’ analyses. Individuals with missing
information with regard to vaccination status (according to our definitions) were excluded from the
analyses. Individuals with missing data with regard to adjustment variables were excluded from models
that included those variables. The results from the models, which included different adjustment variables,
were compared by fitting the simpler models on both the maximum possible number of individuals for the
model in question and on the subset of individuals on whom more fully adjusted models were fitted.
Given the presence of some missing data, especially vaccination records, further analyses including use of
scar information and possibly multiple imputation will be explored. These analyses are not reported here.
Results: pilot study
Main results from the pilot study
The response rates in the pilot study were estimated as 59% for the infant BCG cases and 33% for the
school-age BCG cases (Table 6). The refusal rates were similar between the two studies and were consistent
with community-based studies (about 10%), with the difference in response rates predominantly the result
of non-contact, mainly because of address changes. This was not unexpected as the target population for
the school-age BCG study included more young and middle-age adults of working age and, hence, they
were likely to be more mobile.
Fewer than one in four infant BCG study cases and fewer than one in three school-age BCG study cases
were willing and/or able to nominate two or more potential controls and 29% and 26%, respectively,
were unable to suggest any acquaintance (Table 7). Furthermore, of the total nominated acquaintances,
we were able to recruit only 50% (17/34) for the infant BCG study and 35% (8/23) for the school-age
TABLE 7 Results of the nominated control strategy
Number of controls nominated
per case recruited
BCG sample, n (%)
Infant (N= 34) School-age (N= 19)
0 10 (29) 5 (26)
1 16 (47) 8 (42)
2–5 8 (24) 6 (32)
TABLE 6 Response rates in cases
Outcome
BCG sample
Infant School-age
Total invited, n 58 57
Could not be contacted, n (%) 17 (29) 32 (56)
Contacted but refused to take part, n (%) 7 (12) 6 (11)
Successfully recruited, n (%) 34 (59) 19 (33)
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BCG study. A further challenge was the time needed to recruit each control, as nominated acquaintances
(when more than one) could not all be contacted concomitantly.
The data collection tools and study procedures worked well and required only minor alterations.
Conclusions of the pilot study
The two main conclusions from the pilot study were as follows.
1. Nomination of acquaintances by cases was unlikely to be effective in recruiting controls in this context.
The low recruitment rate for controls using this method was partly because of the paucity of friends
of cases of a similar age as well as people not wanting to risk any potential disclosure of past health
issues. We decided instead to use the alternative, already-planned, community-based controls.
2. The low recruitment rate of cases in the PILOT school BCG study (35% of those invited) suggested a
reduction in the number of cases expected to be recruited even if all those eligible and notified to the
ETS system were invited. This led us to adjust the sample size by increasing the ratio of controls to
cases, from one control per case to two controls per case.
Results: concordance between different measures of bacillus
Calmette–Guérin vaccination
These results are based on eligible participants successfully recruited to the respective studies, as detailed
in the subsequent sections. For the infant BCG study, it was found that participants had difficulties
distinguishing BCG vaccination in infancy from other childhood vaccines. As the self-reported vaccination
information was clearly of poor quality, the three other BCG indicators were examined: scar inspection,
personally held records (red book or vaccination card) and NHS records. For the school-age BCG study,
the quality of recall was better, probably because vaccination was offered at an older age, that is, to
schoolchildren aged 12–13 years on average.
Availability of information on indicators of bacillus Calmette–Guérin status
In the infant BCG study, 15% of cases and 10% of controls declined scar inspection. Red books and
vaccination cards were available for 48% of cases and 57% of controls, and NHS records were found for
52% of cases and 40% of controls (Table 8).
TABLE 8 Available information on various BCG indicators in the infant BCG study by group
Variable
Group
Cases (N= 744) Controls (N= 694)
Red book and vaccination card
Available: BCG vaccination not recorded 156 (21.0) 152 (21.9)
Available: BCG vaccination recorded 203 (27.3) 241 (34.7)
Not available 385 (51.7) 301 (43.4)
NHS records
Available: BCG vaccination not recorded 100 (13.4) 72 (10.4)
Available: BCG vaccination recorded 286 (38.4) 209 (30.1)
Not available 358 (48.1) 413 (59.5)
Scar inspection
BCG scar present 207 (27.8) 174 (25.1)
No BCG scar 422 (56.7) 451 (65.0)
Not inspected 115 (15.5) 69 (9.9)
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In the school-age BCG study, self-reported history was available in > 95% of participants and scar
inspection was carried out in > 90% of participants. Vaccination records were unavailable for > 93% of
participants and, thus, could not be used (Table 9).
Agreement between NHS and red book records, and scar inspection and
NHS/red book records in the infant bacillus Calmette–Guérin study
The agreement over BCG vaccination between NHS records and the red book was poor (Table 10),
suggesting different patterns of incompleteness in the two types of records (i.e. it was unlikely that the
absence of BCG vaccination in one record equated to no vaccination). We found that 40% (35/88) of
subjects with no BCG vaccination recorded in their NHS records were vaccinated according to their red
book and 67% (110/163) of those with no BCG vaccination recorded in their red book were vaccinated
according to their NHS record.
TABLE 9 Available information on various BCG indicators in the school-age BCG study by group
Variable
Group, n (%)
Cases (N= 677) Controls (N= 1170)
Self-reported BCG history
History of BCG vaccination 170 (25.1) 169 (14.4)
No history of BCG vaccination 476 (70.3) 954 (81.5)
Do not remember 31 (4.6) 47 (4.0)
Scar inspection
No BCG scar 204 (30.1) 269 (23.0)
BCG scar 424 (62.6) 844 (72.1)
Not inspected 49 (7.2) 57 (4.9)
Red book and vaccination card
Available: BCG vaccination not recorded 29 (4.3) 59 (5.0)
Available: BCG vaccination recorded 6 (0.9) 12 (1.0)
Not available 642 (94.8) 1099 (93.9)
NHS records
Available: BCG vaccination not recorded 20 (2.9) 27 (2.3)
Available: BCG vaccination recorded 16 (2.4) 20 (1.7)
Not available 641 (94.7) 1123 (96.0)
TABLE 10 Agreement between NHS and red book records in the infant BCG study, overall and by group
BCG vaccination in NHS records
BCG vaccination in red book
Overall, n (%) Cases Controls
No Yes No Yes No Yes
No 53 (14.8) 35 (9.8) 35 (17.4) 18 (9.0) 18 (11.5) 17 (10.8)
Yes 110 (30.7) 160 (44.7) 61 (30.3) 87 (43.3) 49 (31.2) 73 (46.5)
κ 0.15 0.20 0.09
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The data also suggested that, for infant vaccination, scar inspection was not very specific compared with
vaccination records (Table 11). Of those with no BCG vaccination recorded in their red book, only 42%
(111/262) had no scar on inspection and, of those with no BCG vaccination recorded in their NHS records,
only 40% (58/146) had no scar on inspection. This proportion was slightly higher when we combined the
records and considered no BCG vaccination recorded in both records as our best evidence of unvaccinated
status: 53% (23/43) of those classified as unvaccinated had no scar on inspection.
Agreement between bacillus Calmette–Guérin vaccination history and the
presence of a scar in the school-age bacillus Calmette–Guérin study
There was good agreement between self-reported history of BCG vaccination and the presence of a scar
among participants in the school-age BCG study (κ = 0.6; Table 12).
Interpretation
Information on BCG vaccination was clearly better for school vaccination than for infant vaccination.
In the infant BCG study it appeared that no single indicator of BCG status was good enough to be used
on its own to define BCG vaccination status, our main exposure. There was some suggestion that
TABLE 11 Concordance between scar inspection and vaccination recordsa in the infant BCG study, overall and
by group
Scar
inspection
Red book, n (%) NHS records, n (%) Combined records, n (%)
BCG
vaccination
recorded
BCG
vaccination
not recorded
BCG
vaccination
recorded
BCG
vaccination
not recorded
BCG
vaccination
recorded
No BCG
vaccination
recorded in both
Cases n = 182 n = 130 n = 248 n = 80 n = 351 n = 28
BCG scar 128 (70.3) 76 (58.5) 183 (73.8) 47 (58.7) 252 (71.8) 14 (50)
No BCG scar 54 (29.7) 54 (41.5) 65 (26.2) 33 (41.3) 99 (28.2) 14 (50)
Controls n = 226 n = 132 n = 188 n = 66 n = 346 n = 15
BCG scar 184 (81.4) 75 (56.8) 152 (80.8) 41 (62.1) 280 (80.9) 6 (40)
No BCG scar 42 (18.6) 57 (43.2) 36 (19.2) 25 (37.9) 66 (19.1) 9 (60)
Overall n = 408 n = 262 n = 436 n = 146 n = 697 n = 43
BCG scar 312 (76.5) 151 (57.6) 335 (76.8) 88 (60.3) 532 (76.3) 20 (46.5)
No BCG scar 96 (23.5) 111 (42.4) 101 (23.2) 58 (39.7) 165 (23.7) 23 (53.5)
a Subjects were defined as being vaccinated if BCG vaccination was reported in either record. They were defined as being
unvaccinated if both records were available and neither reported BCG vaccination.
TABLE 12 Agreement between self-reported BCG vaccination history and presence of a scar in the school-age BCG
study, overall and by group
Scar inspection
Self-reported history of BCG vaccination
Overall, n (%) Cases, n (%) Controls, n (%)
Yes No Yes No Yes No
BCG scar 1181 (70.5) 43 (2.6) 394 (65.1) 16 (2.6) 787 (73.5) 27 (2.5)
No BCG scar 195 (11.6) 257 (15.3) 60 (9.9) 135 (22.3) 135 (12.6) 122 (11.4)
κ 0.60 0.69 0.52
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combining information from both types of vaccination record was helpful. In the school-age BCG study,
data were available on two main indicators, self-reported history and scar inspection, and there was good
agreement between both measures. This suggested that they could be combined to better define BCG
vaccination status.
Results: infant bacillus Calmette–Guérin study
Overview of recruitment
Recruitment of cases
Of the 1390 potentially eligible cases from the ETS system who were invited to take part in the study, it
was possible to contact 1138. Of these, 6% were excluded because they were not born in the UK, they
were away, as reported by a household member, or, during interview, they were noted to have been
vaccinated because of contact with a case of TB. Of the 1076 subjects contacted and eligible, 797 (74%)
were enrolled (Figure 3).
Recruitment of controls
We sampled 7755 residential addresses, of which 1089 (14%) could not be screened to establish eligibility
for the study because they could not be located or were inaccessible, or because no contact could be
established following the standard visit pattern of visiting more than once on different days and more than
once at different times. Among the 6666 addresses that were screened, 1073 (16%) had at least one
eligible resident, with 694 (65%) eligible subjects successfully recruited to the control group (Figure 4).
Comparison of recruitment between cases and controls
The proportion of cases who could be contacted was fairly comparable across quintiles of area-level IMD
(Table 13). Among those contacted and eligible, the refusal rate did not vary much by quintile of IMD.
Cases identified from ETS 
database 2003–12
(n = 1390)
Contact made
(n = 1138, 81.9%)
No contacta made
(n = 252, 18.1%)
Eligible
(n = 1076, 94.6%)
Successfuld
(n = 797, 74.1%)
Ineligibleb/otherc difficulties
(n = 62, 5.4%)
Refused
(n = 279, 25.9%)
FIGURE 3 Overview of recruitment of infant BCG cases. a, No contact because changed address (n= 142), no
contact with anybody at the address provided (n= 87), moved from England to another part of the UK (n= 10),
moved abroad (n= 8) or unspecified (n= 5). b, Ineligible because not born in the UK (n= 20), not from a BAME
group (n= 2), reported contact with a TB case in the red book and consistent with the date of TB diagnosis on the
ETS system (n= 2) or unspecified (n= 5). c, Other difficulties include away or in hospital during the survey (n= 22),
too frail to take part (n= 5) and various other difficulties (n= 6). d, In total, 797 cases were successfully recruited
but 53 were not included in the analysis because they developed TB before they had a chance to receive the BCG
vaccination (i.e. before their first birthday).
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Similarly, the proportion of addresses successfully screened for eligibility was similar across quintiles of
IMD. Among subjects identified as being eligible to be controls, there was a similar trend for refusal as for
cases, but the refusal rate was consistently higher for controls than for cases.
The distribution of interviewer visits by time of the day and day of the week was also comparable between
cases and controls (Figure 5).
Household addresses sampled
(n = 7755)
Screened
(n = 6666, 86.0%)
Not screeneda
(n = 1089, 14.0%)
Eligible
(n = 1073, 16.1%)
Included
(n = 694, 64.7%)
Ineligibleb
(n = 5593, 83.9%)
Refused
(n = 379, 35.3%)
FIGURE 4 Overview of recruitment of infant BCG controls. a, Not screened because no contact with anybody at the
address provided after several visits following a preset visit pattern. b, Includes 4861 addresses screened with no
eligible subjects and 720 addresses with non-residential, vacant, derelict or demolished buildings.
TABLE 13 Comparison of recruitment of infant BCG cases and controls
Area-level deprivation quintiles
Group
Cases Controls
Cases invited to participate Addresses screened for eligibility
Total, n Contacted, n (%) Total, n Screened, n (%)
Least deprived 159 134 (84) 1556 1377 (88)
2 219 174 (79) 1559 1379 (88)
3 273 217 (79) 1544 1305 (85)
4 330 283 (86) 1547 1307 (84)
Most deprived 407 328 (81) 1549 1298 (84)
Eligible cases contacted Eligible controls contacted
Eligible, n Refused, n (%) Eligible, n Refused, n (%)
Least deprived 125 38 (30) 217 82 (38)
2 160 42 (26) 223 87 (39)
3 205 55 (27) 186 65 (35)
4 271 67 (25) 197 71 (36)
Most deprived 312 76 (24) 250 74 (30)
OBSERVATIONAL STUDIES OF BACILLUS CALMETTE–GUÉRIN VACCINE EFFECTIVENESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
28
Fifty-three subjects who developed TB in the first year of life were censored (i.e. exited the study) before
the start of ‘follow-up’, as some may have developed TB before having the opportunity to receive the
infant BCG vaccination (which could have been offered at any point before the age of 1 year); hence,
these subjects were not included in the analysis. Table 14 shows the number of cases by age range at the
time of TB diagnosis and birth cohort.
Descriptive statistics by case and control status
The distribution of cases and controls by sex and birth cohort was not substantially different; however, there
were more cases than controls with a Pakistani or black African ethnic background (63% vs. 44%) (Table 15).
The distribution of cases by area-level deprivation quintiles and parental education level was consistent
with the known relationship between TB and deprivation, with increasing proportions of cases in the more
deprived quintiles and a higher proportion of cases having parents with fewer educational qualifications.
There were also more cases than controls from overcrowded households. Nearly 95% of the study
participants had a place of residence in infancy or early childhood where infant BCG vaccination was offered,
and this was similar between cases and controls. The distribution of the other variables was also fairly similar.
Indicators of vaccination status
We examined our main definition of BCG vaccination status combining information from the red book and
NHS records (see Table 4). The distribution of BCG vaccination status according to these definitions by case
and control status is presented in Table 16.
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FIGURE 5 Distribution of interviewer visits by (a) time of the day and (b) day of the week for invited cases and
sampled control addresses in the infant BCG study.
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TABLE 14 Distribution of casesa and controlsb in the infant BCG study: number of cases by birth cohort and age
range at the time of TB diagnosis and number of controls from the same birth cohort
Birth cohort Group Total
Time interval since vaccination (years)
1–4 5–9 10–14 15–19
1985–9 Cases 54 – – 9 45
Controls 67 0 0 33 67
1990–4 Cases 188 – 2 72 114
Controls 130 0 55 130 130
1995–9 Cases 202 3 59 109 31
Controls 151 61 151 151 90
2000–4 Cases 189 93 73 17 –
Controls 168 168 168 56 0
2005–11 Cases 117 103 14 – –
Controls 178 178 67 0 0
a The study included cases notified between 2003 and 2012 and aged 1–19 years at the time of diagnosis; therefore,
some birth cohorts do not contribute cases at some follow-up times (left-truncation, e.g. birth cohort 1985–9 would
be aged 13–19 years at the start of ‘follow-up’ in 2003 and so subjects from the birth cohort who developed TB at
age 1–12 years would not be included).
b Controls could contribute observation time to more than one time period; hence, columns by time since vaccination for
controls do not sum to the column totals for controls since vaccination (see Statistical methods for details).
TABLE 15 Characteristics of subjects in the infant BCG study by case/control status
Characteristic
Group, n (%)
Casesa (N= 744) Controls (N= 694)
Birth cohort
1985–9 54 (7.3) 67 (9.7)
1990–4 188 (25.3) 130 (18.7)
1995–9 202 (27.2) 151 (21.8)
2000–4 183 (24.6) 168 (24.2)
2005–11 117 (15.7) 178 (25.6)
Sex
Female 417 (56.0) 350 (50.4)
Male 327 (44.0) 344 (49.6)
Ethnicity
Indian +mixed 146 (19.6) 172 (24.8)
Bangladeshi +mixed 55 (7.4) 79 (11.4)
Pakistani +mixed 323 (43.4) 206 (29.7)
Other Asian +mixed 27 (3.6) 51 (7.3)
Black African +mixed 150 (20.2) 97 (14.0)
Other black+mixed 43 (5.8) 89 (12.8)
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TABLE 15 Characteristics of subjects in the infant BCG study by case/control status (continued )
Characteristic
Group, n (%)
Casesa (N= 744) Controls (N= 694)
Area-level deprivation quintiles
1 (least deprived) 86 (11.6) 139 (20.0)
2 105 (14.1) 140 (20.2)
3 182 (24.5) 139 (20.0)
4 199 (26.7) 141 (20.3)
5 (most deprived) 172 (23.1) 135 (19.5)
Parental highest educational (academic, professional and/or vocational) qualification
None 263 (35.3) 154 (22.2)
O levels or equivalentb 214 (28.8) 160 (23.1)
A levels or equivalentc 88 (11.8) 89 (12.8)
Degree level or equivalentd 142 (19.1) 270 (38.9)
Missing 37 (5.0) 21 (3.0)
Average number of people per room
≤ 1 524 (70.4) 568 (81.8)
> 1 191 (25.7) 126 (18.2)
Missing 29 (3.9) 0 (0.0)
Average number of people per bedroom
≤ 1 104 (14.0) 168 (24.2)
> 1 610 (82.0) 526 (75.8)
Missing 30 (4.3) 0 (0.0)
TB infection risk from regular travels abroad
Lowe 453 (60.9) 434 (62.5)
Highf 289 (38.8) 260 (37.5)
Missing 2 (0.3) 0 (0.0)
TB infection risk from long-term stays abroad
Lowe 637 (85.6) 618 (89.0)
Highf 106 (14.2) 76 (11.0)
Missing 1 (0.1) 0 (0.0)
Infant BCG vaccination policy in health district/PCT of residence up to age 4 years
None 34 (4.6) 39 (5.6)
Selective 502 (67.5) 420 (60.5)
Universal 186 (25.0) 206 (29.7)
Missing 22 (3.0) 29 (4.2)
continued
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Association between time since bacillus Calmette–Guérin vaccination and
tuberculosis (all types, i.e. both pulmonary and non-pulmonary disease)
The detailed uptake of vaccination in cases and controls is presented in Table 17 for each interval of time
since vaccination and by birth cohort stratum; in the analysis, we stratified by year of birth.
Potential confounding variables
There was little evidence of variation in vaccine uptake with covariates in the study data set. There was
some evidence of different uptake by ethnic background and of higher vaccine uptake in participants from
crowded households (Table 18). We did not find a strong correlation between covariates.
TABLE 16 Vaccination status in the infant BCG study based on a combination of red book and NHS records
Red book NHS record
BCG vaccination
status (definition 1)
Group, n (%)
Cases
(N= 744)
Controls
(N= 694)
BCG vaccination recorded BCG vaccination recorded Vaccinated 402 (54.0) 377 (54.3)
BCG vaccination recorded BCG vaccination not recorded
BCG vaccination recorded Missing
BCG vaccination not recorded BCG vaccination recorded
Missing BCG vaccination recorded
BCG vaccination not recorded BCG vaccination not recorded Not vaccinated 35 (4.7) 18 (2.6)
BCG vaccination not recorded Missing Treated as missing 60 (8.1) 85 (12.2)
Missing BCG vaccination not recorded 47 (6.3) 37 (5.3)
Missing Missing Missing 200 (26.9) 177 (25.5)
TABLE 15 Characteristics of subjects in the infant BCG study by case/control status (continued )
Characteristic
Group, n (%)
Casesa (N= 744) Controls (N= 694)
3-year average TB notification rate in local authority or PCT of residence in childhood (per 100,000)
< 20 172 (23.1) 177 (25.5)
20–39 394 (53.0) 299 (43.1)
≥ 40 178 (23.9) 216 (31.1)
Missing 0 (0.0) 2 (0.3)
A level, Advanced level; NVQ, National Vocational Qualification; O level, Ordinary level.
a In total, 53 cases who developed TB in the first year of life exited the study before the start of follow-up at age 1 year.
b O level, General Certificate of Education or General Certificate of Secondary Education (any grade), City & Guilds
Craft/O level or NVQ level 1 or 2.
c A level, Scottish Certificate of Education Higher, Ordinary National Certificate/Ordinary National Diploma/BEC (Business
Education Council)/TEC (Technician Education Council), City & Guilds Advanced Final Level or NVQ level 3.
d Degree level, teaching qualification, Higher National Certificate/Higher National Diploma, BEC/TEC Higher or BTEC
(Business and Technology Education Council) Higher.
e Regular travel (i.e. every few years or more often) to or long-term (> 3-month) stays in Eastern Europe, the Caribbean or
no long-term stays abroad.
f Regular travel (i.e. every few years or more often) to or long-term (> 3-month) stays in Africa or Asia.
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TABLE 18 Association between vaccine uptake (based on combined records) and covariates in the control group
of the infant BCG study
Covariates Vaccinated, n (%) OR 95% CI p-value
Sex
Female (n= 193) 182 (94.3) 1 0.286
Male (n = 202) 195 (96.5) 1.68 0.64 to 4.44
Birth cohort
1985–9 (n= 16) 15 (93.8) 1 0.997
1990–4 (n= 48) 46 (95.8) 1.53 0.13 to 18.1
1995–9 (n= 90) 86 (95.6) 1.43 0.15 to 13.7
2000–4 (n= 102) 97 (95.1) 1.29 0.14 to 11.8
2005–11 (n= 139) 133 (95.7) 1.48 0.17 to 13.11
Ethnic group
Indian (n= 96) 93 (96.9) 1
Bangladeshi (n= 50) 48 (96.0) 0.77 0.13 to 4.8 0.007
Pakistani (n = 133) 131 (98.5) 2.11 0.35 to 12.9
Other Asian (n= 30) 30 (100.0) – –
Black African (n= 56) 50 (89.3) 0.27 0.06 to 1.12
Other black (n = 30) 25 (83.3) 0.16 0.04 to 0.72
continued
TABLE 17 Distribution of observed vaccination status (definition: combined BCG records) in the infant BCG study:
vaccination status in cases by birth cohort and age range at the time of TB diagnosis and in controlsa from the
same birth cohort
Birth cohort Group Total, n/N (%)
Uptake by time since vaccination (years), n/N (%)
1–5 5–10 10–15 15–19
1985–9 Cases vaccinated 16/17 (94) 0 0 2/3 14/14
Controls vaccinated 15/16 (94) 0 0 6/7 15/16
1990–4 Cases vaccinated 78/85 (92) 0 1/1 27/31 50/53
Controls vaccinated 46/48 (96) 0 19/21 46/48 46/48
1995–9 Cases vaccinated 118/125 (94) 3/3 38/39 62/67 15/16
Controls vaccinated 86/90 (96) 40/41 86/90 86/90 46/49
2000–4 Cases vaccinated 107/121 (88) 56/62 42/49 9/10 0
Controls vaccinated 97/102 (95) 97/102 97/102 24/27 0
2005–11 Cases vaccinated 83/89 (93) 73/78 10/11 0 0
Controls vaccinated 133/139 (96) 133/139 48/53 0 0
Total for each time
period since BCG
vaccination, across
birth cohorts
Cases vaccinated 132/143
(92.3)
91/100
(91.0)
100/111
(90.1)
79/83
(95.2)
Controls vaccinated 270/282
(95.7)
250/266
(94.0)
162/172
(94.2)
107/113
(94.7)
a Controls could be used more than once; hence, columns by time since vaccination for controls do not sum to the
column totals for controls (see Statistical methods for details).
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The analyses were stratified by year of birth and ethnic background, thus allowing for the change in
TB rates with age, as well as the known variation in TB rates between ethnic groups.39 The latter also
accounted for any differential uptake in vaccine between ethnic groups. In the multivariable analysis, we
adjusted for those variables associated with vaccine uptake as well as other potential confounders, as
detailed in Statistical methods.
The results of the complete-case analysis (i.e. using only those subjects with vaccine records) are presented
in Table 19. Good evidence of a protective effect of the vaccine was noted in the < 5-year time period and
in the 5- to 10-year period before and after adjusting for confounding (HRadj 0.34, 95% CI 0.15 to 0.78;
TABLE 18 Association between vaccine uptake (based on combined records) and covariates in the control group
of the infant BCG study (continued )
Covariates Vaccinated, n (%) OR 95% CI p-value
Area-level deprivation quintiles
Least deprived (n= 78) 74 (94.9) 1 0.56
2 (n= 79) 77 (97.5) 2.08 0.37 to 11.7
3 (n= 73) 68 (93.2) 0.73 0.19 to 2.8
4 (n= 80) 78 (97.5) 2.11 0.37 to 11.8
Most deprived (n= 85) 80 (94.1) 0.86 0.22 to 3.3
People per bedroom
≤ 1 (n= 75) 67 (89.3) 1 0.011
> 1 (n= 320) 310 (96.9) 3.70 1.41 to 9.73
Highest parental education level
None (n= 90) 87 (96.7) 1 0.56
O level (n= 87) 82 (94.3) 0.56 0.13 to 2.4
A level (n= 52) 51 (98.1) 1.76 0.18 to 17.4
Degree (n= 160) 151 (94.4) 0.58 0.15 to 2.2
A level, Advanced level; O level, Ordinary level; OR, odds ratio.
TABLE 19 Complete-case analysis of the association between time since vaccination and risk of TB using combined
records in the infant BCG study
Time since
vaccination
(years)
Base modela (based on
417 cases and 382 controls)
Base modela restricted to
subjects with no missing
data on covariates (based on
379 cases and 378 controls)
Multivariable adjusted
modelb (based on 379 cases
and 378 controls)
HR (95% CI) p-value HR (95% CI) p-value HR (95% CI) p-value
Unvaccinated 1 (reference) 1 (reference)
1–5 0.38 (0.17 to 0.86) 0.021 0.43 (0.18 to 1.03) 0.058 0.34 (0.15 to 0.78) 0.011
5–10 0.37 (0.15 to 0.88) 0.025 0.32 (0.13 to 0.79) 0.014 0.25 (0.11 to 0.56) 0.001
10–15 0.50 (0.22 to 1.13) 0.096 0.68 (0.28 to 1.66) 0.396 0.64 (0.24 to 1.68) 0.361
15–20 1.25 (0.28 to 5.64) 0.775 2.06 (0.33 to 12.91) 0.440 2.26 (0.34 to 15.10) 0.400
a The base model is stratified on year of birth and ethnic group, and additionally adjusted for sex.
b The multivariable model is additionally adjusted for number of people per bedroom, area-level deprivation quintile and
highest parental educational level.
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p = 0.011; and HRadj 0.25, 95% CI 0.11 to 0.56; p = 0.001, respectively). The evidence for a protective
effect of the vaccine in the time period 10–15 years was weaker, both in the baseline analysis and more so
in the adjusted analysis (HRbaseline 0.50, 95% CI 0.22 to 1.13; p = 0.096; and HRadj 0.64, 95% CI 0.24 to
1.68; p = 0.361, respectively). Examination in a baseline analysis of the effect of vaccination on the smaller
number of records used in the multivariable analysis suggested that this lack of evidence of an effect was
the result of chance (sampling error) rather than the effect of controlling for confounding. Evidence was
lacking for a protective effect 15–20 years after vaccination in both models based on the small numbers
available. CIs were wide, ranging in the baseline analysis from 0.28 to 5.64.
Trends in the association between time since bacillus Calmette–Guérin vaccination and
risk of tuberculosis
Table 20 shows the results from modelling of the association between BCG vaccination and the log-hazard
of TB as a linear function of time since vaccination, centred at 5 years post vaccination. The results are
displayed graphically in Figure 6. The model suggests a 12% increase (95% CI –1% to 26%) in the HR with
each year post vaccination, although this was of only borderline statistical significance. We also explored the
trend in time using restricted cubic splines with three knots, at 5, 10 and 15 years post vaccination. The
results were similar to those found using the linear model and are not shown here. The results suggest a
statistically significant protective effect of the vaccine up to about 10 years post vaccination, with a gradual
reduction in the protective effect up to that time. After 10 years post vaccination, the confidence bounds are
wide and there is insufficient information to draw conclusions about vaccine effectiveness.
TABLE 20 Association between BCG vaccination status and risk of TB in the infant BCG study as a smooth function
of time since vaccination, using the multivariable adjustment model
Time since BCG vaccination HR (95% CI) p-value
Unvaccinated 1 (reference)
HR at 5 years post vaccination 0.32 (0.16 to 0.64) 0.001
Multiplying factor for each year increase in time since vaccination 1.12 (0.99 to 1.26) 0.062
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FIGURE 6 Results from modelling of the time-varying effect of the vaccine as a linear function of time (on the
log-scale) in the infant BCG study. The left-hand vertical axis shows the HR and the right-hand vertical axis shows
the VE, both on the log-scale. The results are based on the multivariable adjusted model. The dashed lines
show the 95% confidence bounds.
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Results: school-age bacillus Calmette–Guérin study
Overview of recruitment
Recruitment of cases
A total of 1602 potentially eligible cases was identified from the ETS system and invited to take part in the
study, of whom 1047 (65%) were successfully contacted. About 11% were not included either because
they were ineligible or because of other difficulties (Figure 7). Of those contacted and eligible, 257 (28%)
declined to participate and 677 (72%) were enrolled.
Recruitment of controls
We sampled 9424 residential addresses, of which 1248 (13%) could not be screened because the address
no longer existed or no-one was contactable at the household after several visits to establish if any of the
residents were eligible for the study (Figure 8). Among the 8176 addresses that were screened, 1790 (22%)
had at least one eligible resident, with 1170 (65%) eligible subjects successfully recruited to the control group.
Comparison of recruitment between cases and controls
The proportion of cases who could be contacted was slightly lower in the more deprived quintiles of
area-level IMD (Table 21). Among those contacted and eligible, the refusal rate was slightly lower in the
lower quintiles of area-level IMD. The proportion of addresses successfully screened for eligible controls
was similar across quintiles of IMD. Among subjects identified as eligible to be controls, the refusal rate
was similar across quintiles. The refusal rate was slightly higher for controls than for cases.
The distribution of interviewer visits by time of the day and day of the week was comparable between
cases and controls (Figure 9).
We found that retrospective ascertainment of the results of the TST was challenging in the school-aged
BCG study, with very poor recall and no records to support or validate participants’ self-reports. Further
investigation of the literature47 indicated that the initially high TB risk in those who were PPD positive
dropped to be the same as that for those who were PPD negative and unvaccinated (see Figure 11).
Cases identified from ETS 
database 2003–12
(n = 1602)
Contact made
(n = 1047, 65.4%)
No contacta made
(n = 555, 34.6%)
Eligible
(n = 934, 89.2%)
Successful
(n = 677, 72.5%)
Ineligibleb/other difficultiesc
(n = 113, 10.8%)
Refused
(n = 257, 27.5%)
FIGURE 7 Overview of recruitment of school-age BCG cases. a, No contact because changed addresses (n= 353), no
contact with anybody at address provided (n= 165), moved from England to another part of the UK (n= 10), moved
abroad (n= 12), inaccessible (n= 6) or unspecified (n= 9). b, Ineligible because not born in the UK (n= 13), not white
(n= 23), reported vaccination at a later age and following contact with a TB case in the red book and consistent with
the date of TB diagnosis on the ETS system (n= 4) or unspecified (n= 20). c, Other difficulties includes away or in
hospital during the survey (n= 23), too frail to take part (n= 20), died (n= 6) and various other difficulties (n= 4).
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Thus, we included all those who were unvaccinated, irrespective of PPD status prior to the offer of
school-aged BCG vaccination.
Descriptive statistics by case and control status
The cases were slightly younger than the controls and were more likely to be male (Table 22). The distribution
of cases by area-level deprivation quintiles and parental education level was consistent with the known
TABLE 21 Comparison of recruitment of school-age BCG cases and controls
Area-level deprivation quintiles
Group
Cases Controls
Cases invited to participatea Addresses screened for eligibility
Total, n Contacted, n (%) Total, n Contacted, n (%)
Least deprived 165 119 (72) 1889 1634 (87)
2 218 157 (72) 1885 1599 (85)
3 233 148 (64) 1886 1631 (86)
4 394 254 (64) 1886 1659 (88)
Most deprived 575 357 (62) 1878 1653 (88)
Eligible cases contacted Eligible controls contacted
Eligible, n Refused, n (%) Eligible, n Refused, n (%)
Least deprived 107 35 (33) 429 155 (36)
2 146 36 (25) 363 130 (36)
3 137 35 (26) 358 127 (35)
4 217 63 (29) 359 113 (31)
Most deprived 316 86 (27) 281 95 (34)
a Seventeen could not be allocated a deprivation index as the postcode no longer existed.
Household addresses sampled
(n = 9424)
Screened
(n = 8176, 86.8%)
Not screeneda
(n = 1248, 13.2%)
Eligible
(n = 1790, 21.9%)
Successful
(n = 1170, 65.4%)
Ineligibleb
(n = 6386, 78.1%)
Refused
(n = 620, 34.6%)
FIGURE 8 Overview of recruitment of school-age BCG controls. a, Not screened because no contact with anybody
at the address provided after several visits following the preset visit pattern. b, Includes 5692 addresses screened
with no eligible subjects and 694 addresses with non-residential, vacant, derelict or demolished buildings.
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FIGURE 9 Distribution of interviewer visits by (a) time of the day and (b) day of the week for invited cases and
sampled control addresses in the school-age BCG study.
TABLE 22 Characteristics of subjects in the school-age BCG study by case/control status
Characteristic
Group, n (%)
Cases (N= 677) Controls (N= 1170)
Birth cohort
1965–9 65 (9.6) 174 (14.9)
1970–4 178 (26.3) 312 (26.7)
1975–9 215 (31.8) 260 (22.2)
1980–9 219 (32.3) 424 (36.2)
Sex
Female 341 (50.4) 700 (59.8)
Male 336 (49.6) 470 (40.2)
Area-level deprivation quintiles
1 (least deprived) 63 (9.3) 234 (20.0)
2 99 (14.6) 234 (20.0)
3 109 (16.1) 234 (20.0)
4 130 (19.2) 234 (20.0)
5 (most deprived) 276 (40.8) 234 (20.0)
OBSERVATIONAL STUDIES OF BACILLUS CALMETTE–GUÉRIN VACCINE EFFECTIVENESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
38
TABLE 22 Characteristics of subjects in the school-age BCG study by case/control status (continued )
Characteristic
Group, n (%)
Cases (N= 677) Controls (N= 1170)
Highest educational (academic, professional and/or vocational) qualification
None 132 (19.5) 75 (6.4)
O level or equivalenta 207 (30.6) 363 (31.0)
A level or equivalentb 91 (13.4) 246 (21.0)
Degree level or equivalentc 216 (31.9) 455 (38.9)
Missing 31 (4.6) 31 (2.6)
Average number of people per room
≤ 1 634 (93.6) 1144 (97.8)
> 1 26 (3.8) 24 (2.1)
Missing 17 (2.5) 2 (0.2)
Average number of people per bedroom
≤ 1 385 (56.9) 705 (60.3)
> 1 275 (40.6) 463 (39.6)
Missing 17 (2.5) 2 (0.2)
TB infection risk from regular travels abroad
Lowd 618 (91.3) 1099 (93.9)
Highe 58 (8.6) 71 (6.1)
Missing 1 (0.1) 0 (0.0)
TB infection risk from long-term stays abroad
Lowd 607 (89.7) 1113 (95.1)
Highe 70 (10.3) 57 (4.9)
Alcohol consumptionf
Very low/no risk 166 (24.5) 329 (28.1)
Low risk 346 (51.1) 632 (54.0)
Hazardous risk 36 (5.3) 68 (5.8)
Harmful risk 41 (6.1) 25 (2.1)
Missing 88 (13.0) 116 (9.9)
Tobacco smoking
Never smoker 188 (27.8) 499 (42.6)
Ex-smoker 62 (9.2) 135 (11.5)
Smoker: < 20 pack-years 308 (45.5) 422 (36.1)
Smoker: ≥ 20 pack-years 99 (14.6) 85 (7.3)
Missing 20 (3.0) 29 (2.5)
Drug misuse/abuse
g
No drug use 379 (56.0) 847 (72.4)
Class B and/or C use only 69 (10.2) 108 (9.2)
Class A use 217 (32.1) 188 (16.1)
Missing 12 (1.8) 27 (2.3)
continued
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association of TB with deprivation, with a higher proportion of cases than controls in the most deprived
quintile and a higher proportion of cases than controls with fewer educational qualifications. There were
also slightly more cases than controls from overcrowded households. Cases were slightly more likely than
controls to have regularly travelled to a high-risk area and were somewhat more likely than controls to
have had a long-term stay in a high-risk area. A higher proportion of cases than controls reported drinking
at a hazardous or harmful level and being a smoker. A much higher proportion of cases than controls
reported having used class A drugs. Cases were also more likely than controls to report a history of
homelessness for ≥ 1 week and a history of prison detention in the UK or abroad.
Indicators of vaccination status
The availability of the various indicators of BCG status is presented in Table 23. As noted earlier (see Table 12),
self-report of BCG vaccination at school was judged to be more accurate than self-report or parental report
of infant BCG vaccination. Both personal and NHS records were missing for > 90% of study participants in
the school-aged BCG study and insufficient information was available to allow any formal assessment of the
validity of either of these measures. There was, however, a good level of agreement between self-reported
history and scar inspection. These two indicators were therefore combined to define BCG status in this
study (Table 24).
Association between time since bacillus Calmette–Guérin vaccination and all cases of
tuberculosis: complete-case analysis
The distribution of case and control subjects by vaccination status and time since vaccination is presented
in Table 25. There was strong evidence of a protective effect of the vaccine in each of the 5-year periods
TABLE 22 Characteristics of subjects in the school-age BCG study by case/control status (continued )
Characteristic
Group, n (%)
Cases (N= 677) Controls (N= 1170)
History of homelessness
Never been homeless for ≥ 1 week 553 (81.7) 1091 (93.2)
Ever been homeless for ≥ 1 week 117 (17.3) 68 (5.8)
Missing 7 (1.0) 11 (0.9)
History of prison stayh
Never detained 590 (87.1) 1119 (95.6)
Ever detained in the UK or abroad 82 (12.1) 35 (3.0)
Missing 5 (0.7) 16 (1.4)
A level, Advanced level; NVQ, National Vocational Qualification; O level, Ordinary level.
a O level, General Certificate of Education or General Certificate of Secondary Education (any grade), City & Guilds
Craft/O level or NVQ level 1 or 2.
b A level, Scottish Certificate of Education Higher, Ordinary National Certificate/Ordinary National Diploma/BEC
(Business Education Council)/TEC (Technician Education Council), City & Guilds Advanced Final Level or NVQ level 3.
c Degree level, teaching qualification, Higher National Certificate/Higher National Diploma, BEC/TEC Higher or BTEC
(Business and Technology Education Council) Higher.
d Regular travel (i.e. every few years or more often) to or long-term (> 3-month) stays in Eastern Europe, Caribbean or no
long-term stays abroad.
e Regular travel (i.e. every few years or more often) to or long-term (> 3-month) stays in Africa or Asia.
f Alcohol consumption based on a combination of drinking frequency and quantity in UK standard units, using cut-off
points by sex as proposed by Rehm et al.40 Cut-off points for hazardous and harmful drinking were 20 g/day and 40 g/day,
respectively, for women and 40 g/day and 60 g/day, respectively, for men. Subjects who stopped drinking ≥ 5 years
previously were classified as low risk.
g Class B and class C examples included benzodiazepines, cannabis, qat, glue, gas, solvents and amphetamines. Class A
examples included ecstasy, cocaine, crack, heroin, LSD (lysergic acid diethylamide) and magic mushrooms.
h A total of 72/82 (88%) cases and 33/35 (94%) controls with a history of a prison stay reported only ever having been in
prison in the UK and not abroad.
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TABLE 24 Vaccination status in the school-age BCG study based on combination of self-report and scar reading
Self-reported history Scar inspection
BCG vaccination
status
Group, n (%)
Cases
(N= 677)
Controls
(N= 1170)
Convincing BCG history Scar present Vaccinated 473 (69.9) 933 (79.7)
Convincing BCG history No scar
Convincing BCG history Not inspected
Probable BCG history Scar present
Probable BCG history No scar Likely vaccinateda 33 (4.9) 78 (6.7)
Probable BCG history Not inspected
No BCG history Scar present
Unsure Scar present
No BCG history No scar Not vaccinated 163 (24.1) 154 (13.2)
No BCG history Not inspected
Unsure No scar
Unsure Not inspected Missing 8 (1.2) 5 (0.4)
a Sensitivity analysis moving these participants to the vaccinated category did not change the effect estimate of the
association between BCG vaccination and TB and had small numbers; these participants were therefore assigned to the
vaccinated category for the rest of the analyses.
TABLE 23 Availability of BCG indicators in the school-age BCG study by case/control status
Indicator
Group, n (%)
Cases (N= 677) Controls (N= 1170)
BCG vaccination history
Vaccinated 470 (69.4) 922 (78.8)
Probably vaccinated 6 (0.9) 32 (2.7)
Not vaccinated 170 (25.1) 169 (14.4)
Missing 31 (4.6) 47 (4.0)
Scar inspection
BCG scar 424 (62.6) 844 (72.1)
No BCG scar 204 (30.1) 269 (23.0)
Not inspected 49 (7.2) 57 (4.9)
Personal vaccination record
BCG vaccination recorded 6 (0.9) 12 (1.0)
BCG vaccination not recorded 29 (4.3) 59 (5.0)
No personal record 642 (94.8) 1099 (93.9)
NHS vaccination records
BCG vaccination recorded 16 (2.4) 20 (1.7)
BCG vaccination not recorded 20 (3.0) 27 (2.3)
NHS record missing 641 (94.7) 1123 (96.0)
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from 10 to 20 years post vaccination (Table 26). Results from the model fully adjusted for confounders
provided evidence of a protective effect 10–15 years (HRadj 0.49, 95% CI 0.31 to 0.79; p = 0.003) and
15–20 years (HRadj 0.43, 95% CI 0.28 to 0.67; p < 0.001) after vaccination compared with > 20 years after
vaccination. The numbers were too small to assess the effect from 20 to 25 years but there was a
suggestion of a protective effect.
These results are based on a complete-case analysis (i.e. based on subjects with no missing data). Missing
information may be explored in a future analysis.
Trends in the association between time since bacillus Calmette–Guérin
vaccination and risk of tuberculosis
Table 27 shows the results from modelling of the association between BCG vaccination and log-hazard of
TB as a linear function of time since vaccination, centred at 10 years post vaccination. The results are
displayed graphically in Figure 10. The model suggests a 7% increase (95% CI 0.2% to 12%) in the HR
with each year post vaccination and this was statistically significant. We also explored the trend in time
using restricted cubic splines with three knots, at 15, 20 and 25 years post vaccination. The results were
similar to those found using the linear model and are not shown here.
The results showed a statistically significant protective effect of the vaccine up to about 23 years
post vaccination, with a gradual reduction in the protective effect up to that time. The protective effect
of the vaccine appears to reduce more steeply after about 20 years post vaccination. However, we had
only a relatively small number of cases with > 25 years post vaccination and, thus, have insufficient
evidence to assess protection beyond that time.
TABLE 25 Distribution of observed vaccination status (definition: combined BCG history and scar inspection) in the
school-age BCG study: vaccination status in cases by birth cohort and age range at the time of TB diagnosis and in
controlsa from the same birth cohort
Birth cohort Group Total, n/N (%)
Uptake by time since vaccination (years), n/N (%)
10–15 15–20 20–25 25–29
1965–9 Cases vaccinated 51/64 (79.7) – – 32/39 19/25
Controls vaccinated 147/173 (85.0) 0 0 124/144 147/173
1970–4 Cases vaccinated 136/174 (78.2) – 28/34 93/120 15/20
Controls vaccinated 262/311 (84.2) 0 208/259 262/311 262/311
1975–9 Cases vaccinated 161/212 (75.9) 33/46 66/81 61/84 1/1
Controls vaccinated 231/259 (89.2) 231/259 231/259 231/259 55/64
1980–9 Cases vaccinated 158/219 (72.1) 121/159 37/59 0/1 –
Controls vaccinated 371/422 (87.9) 371/422 236/259 48/55 0
Total for each time
period since BCG
vaccination, across
birth cohorts
Cases vaccinated 154/205
(75.1)
131/174
(75.3)
186/244
(76.2)
35/46
(76.1)
a Controls could be used more than once; hence, columns by time since vaccination for controls do not sum to the
column totals for controls (see Statistical methods for details).
OBSERVATIONAL STUDIES OF BACILLUS CALMETTE–GUÉRIN VACCINE EFFECTIVENESS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
42
TA
B
LE
26
C
o
m
p
le
te
-c
as
e
an
al
ys
is
o
f
th
e
as
so
ci
at
io
n
b
et
w
ee
n
ti
m
e
si
n
ce
va
cc
in
at
io
n
an
d
ri
sk
o
f
TB
u
si
n
g
va
ri
o
u
s
d
ef
in
it
io
n
s
fo
r
B
C
G
st
at
u
s
in
th
e
sc
h
o
o
l-
ag
e
B
C
G
st
u
d
y
Ti
m
e
si
n
ce
va
cc
in
at
io
n
(y
ea
rs
)
B
as
e
m
o
d
el
a
(b
as
ed
o
n
66
9
ca
se
s
an
d
11
65
co
n
tr
o
ls
)
Pa
rt
ia
lly
ad
ju
st
ed
m
o
d
el
b
(b
as
ed
o
n
63
8
ca
se
s
an
d
11
34
co
n
tr
o
ls
)
Fu
lly
ad
ju
st
ed
m
o
d
el
c
(b
as
ed
o
n
53
2
ca
se
s
an
d
99
3
co
n
tr
o
ls
)
B
as
e
m
o
d
el
a
fi
tt
ed
o
n
sa
m
e
su
b
se
t
as
in
fu
lly
ad
ju
st
ed
m
o
d
el
c
(b
as
ed
o
n
53
2
ca
se
s
an
d
99
3
co
n
tr
o
ls
)
Pa
rt
ia
lly
ad
ju
st
ed
m
o
d
el
b
fi
tt
ed
o
n
sa
m
e
su
b
se
t
as
in
fu
lly
ad
ju
st
ed
m
o
d
el
c
(b
as
ed
o
n
53
2
ca
se
s
an
d
99
3
co
n
tr
o
ls
)
H
R
(9
5%
C
I)
p
-v
al
u
e
H
R
(9
5%
C
I)
p
-v
al
u
e
H
R
(9
5%
C
I)
p
-v
al
u
e
H
R
(9
5%
C
I)
p
-v
al
u
e
H
R
(9
5%
C
I)
p
-v
al
u
e
U
nv
ac
ci
na
te
d
1
(r
ef
er
en
ce
)
1
(r
ef
er
en
ce
)
1
(r
ef
er
en
ce
)
1
(r
ef
er
en
ce
)
1
(r
ef
er
en
ce
)
10
–
15
0.
40
0
(0
.2
74
to
0.
58
4)
0.
00
0
0.
41
9
(0
.2
72
to
0.
64
4)
0.
00
0
0.
49
(0
.3
1
to
0.
79
)
0.
00
3
0.
43
(0
.2
8
to
0.
66
)
<
0.
00
1
0.
49
(0
.3
1
to
0.
79
)
0.
00
4
15
–
20
0.
34
6
(0
.2
46
to
0.
48
7)
0.
00
0
0.
39
0
(0
.2
64
to
0.
57
5)
0.
00
0
0.
43
(0
.2
8
to
0.
67
)
<
0.
00
1
0.
34
(0
.2
3
to
0.
50
)
<
0.
00
1
0.
41
(0
.2
7
to
0.
63
)
<
0.
00
1
20
–
25
0.
55
4
(0
.4
04
to
0.
75
9)
0.
00
0
0.
64
0
(0
.4
48
to
0.
91
6)
0.
01
5
0.
75
(0
.4
9
to
1.
14
)
0.
17
4
0.
56
(0
.3
9
to
0.
80
)
0.
00
1
0.
69
(0
.4
6
to
1.
02
)
0.
06
5
25
–
29
0.
56
5
(0
.3
42
to
0.
93
2)
0.
02
5
0.
77
2
(0
.4
53
to
1.
31
5)
0.
34
1
0.
99
(0
.5
3
to
1.
84
)
0.
97
0.
70
(0
.4
0
to
1.
24
)
0.
22
5
0.
88
(0
.4
8
to
1.
59
)
0.
66
a
Th
e
ba
se
m
od
el
is
st
ra
tif
ie
d
on
bi
rt
h
co
ho
rt
an
d
ad
ju
st
ed
fo
r
se
x.
b
Th
e
pa
rt
ia
lly
ad
ju
st
ed
m
od
el
is
ad
di
tio
na
lly
ad
ju
st
ed
fo
r
th
e
co
nf
ou
nd
in
g
va
ria
bl
es
ar
ea
-le
ve
ld
ep
riv
at
io
n
an
d
ed
uc
at
io
na
ll
ev
el
.
c
Th
e
fu
lly
ad
ju
st
ed
m
od
el
is
fu
rt
he
r
ad
ju
st
ed
fo
r
th
e
co
nf
ou
nd
in
g
va
ria
bl
es
ar
ea
-le
ve
ld
ep
riv
at
io
n
an
d
ed
uc
at
io
na
ll
ev
el
,
lif
es
ty
le
va
ria
bl
es
(t
ob
ac
co
sm
ok
in
g,
al
co
ho
lc
on
su
m
pt
io
n
an
d
m
is
us
e/
ab
us
e
of
co
nt
ro
lle
d
dr
ug
s)
,
hi
st
or
y
of
ho
m
el
es
sn
es
s,
hi
st
or
y
of
pr
is
on
st
ay
s
an
d
TB
in
fe
ct
io
n
ris
k
fr
om
re
gu
la
r
tr
av
el
s
ab
ro
ad
.
DOI: 10.3310/hta21390 HEALTH TECHNOLOGY ASSESSMENT 2017 VOL. 21 NO. 39
© Queen’s Printer and Controller of HMSO 2017. This work was produced by Mangtani et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
43
Discussion
The results from our studies of the duration of protection of BCG vaccination indicate that protection
persists for at least 10 years for infant vaccination in a population at high risk for TB and for at least
20 years for school-age vaccination in a low-risk population. A protective effect of 48% (95% CI 17% to
68%) was seen 10–15 years after school-age BCG vaccination and a protective effect of 55% (95% CI
30 to 71%) was seen 15–20 years after school-age vaccination, beyond which protection appeared to wane.
For infant BCG vaccination, a protective effect was seen for up to 10 years post vaccination (< 5 years post
vaccination: VE 66%, 95% CI 17% to 86%; 5–10 years post vaccination: VE 75%, 95% CI 43% to 89%),
but there was less evidence of an effect 10–15 post vaccination (VE 36%, 95% CI negative to 77%;
p = 0.396). In the infant BCG study, in the analysis adjusted for several confounders, including birth cohort
and ethnicity, the results were based on subjects for whom vaccine records were available. By adjusting
TABLE 27 Association between BCG vaccination status and risk of TB in the school-age study as a smooth function
of time since vaccination
Time since BCG vaccination
Adjusted model
Partiallya Fullyb
HR (95% CI) p-value HR (95% CI) p-value
Unvaccinated 1 (reference) 1 (reference)
HR at 10 years post vaccination 0.310 (0.188 to 0.511) 0.000 0.374 (0.215 to 0.652) 0.001
Multiplying factor for each year increase
in time since vaccination
1.07 (1.00 to 1.12) 0.015 1.057 (1.002 to 1.116) 0.042
a The partially adjusted model is stratified on birth cohort and adjusted for the confounding variables of sex, area-level
deprivation and educational level.
b The fully adjusted model is further adjusted for the confounding variables of area-level deprivation and educational level,
lifestyle variables (tobacco smoking, alcohol consumption and misuse/abuse of controlled drugs), history of homelessness,
history of prison stays and TB infection risk from regular travels abroad.
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FIGURE 10 Results from modelling of the time-varying effect of the vaccine as a linear function of time (on the
log-scale) in the school-age study. The left-hand vertical axis shows the HR and the right-hand vertical axis shows
the VE, both on the log-scale. The results are based on the multivariable adjusted model. The dashed lines show
the 95% confidence bounds.
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only for ethnicity and birth cohort, slightly more records with complete data could be included, giving weak
evidence of 50% VE (95% CI negative to 78%; p = 0.096) 10–15 years post vaccination. The higher than
expected infant BCG vaccine uptake rate in this high-risk ethnic minority study population and the sparsity
of vaccine record data in the later time periods precluded further assessment.
The study findings are consistent with recent findings from Norway41 and Brazil,25 and provide additional
evidence to that from the seminal MRC trial,7 in which protection of 63% was seen 10–15 years after
vaccination, with wide CIs (95% CI 17% to 84%), with no evidence of protection 15–20 years after
vaccination (VE 9%, 95% CI negative to 71%).
The BCG vaccine composition and changes in administration were not considered to be important sources of
variation over the study period. Although the Danish liquid BCG vaccine was replaced in the UK in the 1960s
by the Glaxo freeze-dried BCG vaccine (Glaxo 1077 vaccine strain developed by Glaxo from the Danish
strain and produced in the UK by Evans-Medeva), a study comparing both showed non-inferiority.42,43
From 2002, the UK has been able to source the BCG vaccine only from Denmark’s Statens Serum Institut
(SSI vaccine, also based on the Danish strain 1331).44 A recent systematic review of the BCG vaccine trials
by our research group also suggested that protection did not vary by vaccine strain.10 Multipuncture
vaccination use was limited. In our analysis of policy we noted that the 1983 survey indicated that 76% of
districts used intradermal BCG vaccination, which increased in the 1992 survey to 96% of districts. No data
were available comparing protection using multipuncture with protection using intradermal vaccination,
but sensitisation based on the TST was similar.45,46
There was a good response rate in both studies and we were able to successfully recruit population-based
controls to represent both the children born in the UK to populations from high TB burden settings and the
general population. We were unable to link to vaccine records for most of the school-aged BCG subjects,
despite their willingness to consent to such linkage. Self-reported history of BCG vaccination and scar
inspection were used instead to measure BCG vaccine uptake, having been found to have good agreement
with each other (this agreement was not observed, by contrast, in those offered the BCG vaccine in infancy).
Although interviewers were not blind to case–control status or to knowledge of a history of BCG vaccination
before scar reading, they were specifically trained to identify a BCG scar, which included examining volunteers
with and without scars. In addition, 10% of interviews selected at random were checked by senior staff
and standardised reporting was required. The interviewers were aware that the study was to assess the
duration of protection from BCG. As there was little information on how long BCG protects, it is unlikely
that the interviewers would have been biased in one direction with the presence or absence of a BCG scar.
There was some confounding because of lower BCG vaccine uptake in poorer subjects, who had a higher
risk of TB. We were, however, able to control for this.
We were able to evaluate the effectiveness of the BCG vaccine in BAME population groups despite initial
concerns that this group would be difficult to assess. Consent was obtained to link to vaccine records,
but records could be retrieved for only about half of the participants, from either NHS administrative areas
or patient-held records. There was a considerable lack of agreement between the different sources of
information on infant BCG vaccination. In the infant study, self-reported BCG vaccine uptake was also
found to be a poor measure of vaccination and scar reading was poorly concordant with vaccine records,
when available. Red book and NHS records also had poor concordance, indicating that BCG vaccination
was being noted in one record but not necessarily the other. We also noted a higher refusal rate for
reading a BCG scar in some BAME young adult female cases, who were not comfortable having their
upper arms examined compared with controls. For reasons of poor concordance of the two sources of
records and probably biased assessments of scars, we therefore used vaccine records when available,
despite not having information on uptake for about 40% of subjects. Future work may include exploring
different approaches to determine vaccination status, which could include scar reading, despite the
relatively poor specificity of scar reading noted in this study, to reduce the level of missing information on
vaccination status in the infant vaccination study.
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Addressing the issue of prior infection as the reason for not receiving bacillus
Calmette–Guérin vaccination
A theoretical limitation in the school-age BCG study was the inability to assess, and exclude, controls for
a prior positive TST. Retrospective ascertainment of TST results based on recall was clearly not feasible
and there were no records to validate participants’ memory recall. Under the routine school vaccination
programme, prior infection by M. tuberculosis or sensitisation by environmental mycobacteria was
investigated through the TST and such subjects were not offered the BCG vaccine. These subjects are
usually not included in studies measuring the effect of the BCG vaccine in the short term, as there is
evidence that the risk of TB is higher in TST-positive subjects during the first few years after infection.
Their inclusion would, thus, act to overestimate the protective effect of BCG vaccination. It is also thought
that the BCG vaccine does not confer protection in TST-positive subjects. However, follow-up data from
the UK MRC BCG trial of adolescents7,47 showed that, at least in settings with a low transmission rate, the
risk of TB in TST-positive participants declined over time and was similar to that of subjects who were TST
negative at baseline by about 10 years after enrolment (Figure 11). Thus, the TST was thought unlikely to
play a major role when measuring the association between BCG vaccination and TB beyond 10 years after
vaccination, as in our study. Extrapolation of earlier modelling work by one of the authors of the paper
(extrapolation not published)48 and this report also suggested that the prevalence of tuberculin positivity in
the white population in general would have been around 4% at the time of screening for vaccination.
Conclusions
In summary, our two observational studies suggest that BCG vaccination provides longer-lasting protection
than previously described, particularly for BCG vaccination at school age, for which we were able to use
scar identification and history as measures of BCG uptake. Protection was noted for more than two
decades after vaccination, but waned 20–25 years after vaccination. The findings are consistent with the
limited data emerging from other trials and observational studies,23 as well as from a more recent Norwegian
historical cohort study of the duration of protection of the BCG vaccine.41 BCG vaccination at school age may
thus have helped in the control of TB, including reducing the potential for developing multidrug-resistant
disease, as those vaccinated at about 13 years of age have moved into adulthood.
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FIGURE 11 Comparison of TB rates in vaccinated and unvaccinated subjects by TST status at the start of follow-up in
the UK MRC BCG trial of adolescents. TU, tuberculin units. Figure based on data from the UK MRC trial published in
the Fourth Report to the Medical Research Council by its Tuberculosis Vaccines Clinical Trials Committee.47
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Our current analysis of the infant BCG study, based on just over 50% of the subjects with vaccine records
and complete information on covariates, was able to confirm the known protective effect of infant BCG
vaccination against TB for up to 10 years after vaccination, adjusting for confounders. However, numbers
were too sparse after 10 years to provide robust evidence of VE for this time period. Vaccine coverage
was higher than expected in those with records. Further exploratory analyses to deal with missing records
could include multiple imputation of missing BCG vaccination status, among other sensitivity analyses. This
assessment might inform a review of incidence levels when countries are recommended to suspend BCG
vaccination, as well as estimates of the cost-effectiveness of the BCG vaccine in the prevention of TB, and
might have implications for the testing and scheduling of new vaccines against TB, which will need to
provide better protection than the BCG vaccine and be as durable. More systematic recording of BCG
vaccine uptake at the population level by ethnic group using the CHIS and linkage to TB events could help
to provide ongoing data for assessing protection and the duration of protection over the life course.
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